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Abstract 
 The fuscachelins are a group of novel small molecule secondary metabolites 
produced by the thermophilic actinomycete Thermobifida fusca.  A genome mining 
approach was employed to identify the fuscachelin nonribosomal peptide synthetase 
biosynthetic gene cluster in T. fusca.  The peptide natural products were predicted to be 
siderophores, iron-scavenging small molecules.  An assay guided fractionation approach 
was utilized to isolate the fuscachelins.  Structure elucidation efforts employed nuclear 
magnetic resonance, mass spectrometric and chemical degradation techniques to 
determine the structure of the isolated compounds.  Once the structure was known, a 
total synthesis was undertaken.  The established synthetic route to the fuscachelins will 
allow for the facile development of custom-designed chemical tools for the further study 
of the fuscachelin biosynthetic enzymes and utilization proteins.   
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Chapter 1 
 
An Introduction to Bacterial Secondary 
Metabolism & Nonribosomal Peptide 
Biosynthesis, with an Emphasis on Siderophore 
Secondary Metabolites 
 2 
Introduction 
One could not overemphasize the impact that naturally occurring small molecules 
have on the biosphere.  From mediating seemingly simple intraspecies interactions to 
dictating complex ecological systems, modern biological and chemical research has 
unveiled the apparently ubiquitous role of natural products in the environment.  Likewise, 
the impact that these compounds have had on society has been profound.  Everyone 
has, for instance, experienced the “earthy” smell generated by the terpene geosmin, (1) 
a product of soil-dwelling bacteria (Fig. 1.1).1  The opium alkaloid morphine (2), 
produced by the poppy plant Papaver somniferum, has a long history of both beneficial 
and profoundly negative medical, social, economic and political consequences as it has 
been exploited both for its use as a powerful analgesic and for its elaboration to the drug 
heroine.2 The structural complexity of polyketides like monensin (3) have inspired and 
driven synthetic chemists to the point where virtually any molecule is now considered 
synthetically accessible.3-5  The discovery of the nonribosomal peptide antibiotic 
penicillin (4) in 1928 by Alexander Fleming ushered in a new era of antibiotic drug 
discovery and seemed, at the time, to eradicate some of civilization’s most feared 
diseases.6   
Indeed, over the course of the 1940s and 50s, the so-called “golden age” of 
antibiotic discovery, it became obvious that natural products could fuel the engines of 
discovery and profit in both academic and industrial circles.  In line with the adoption of 
combinatorial chemistry by industry and the continued “re-isolation” of known small 
molecules, the later part of the twentieth century saw a decline in the isolation and 
efforts toward the discovery of new natural products.7  In the current “post-genomic” era 
of the twenty-first century, new chemical, genetic and technological tools are rapidly  
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paving new inroads towards the discovery of novel small molecules.  It is the purpose of 
this dissertation to illustrate the application of these new tools as they relate to the 
discovery of a set of unique nonribosomal peptides, the fuscachelins (Fig. 1.2, 5-7), 
products of the terrestrial, thermophilic actinomycete Thermobifida fusca.8 
Bacterial Secondary Metabolism 
When Fleming discovered zones of growth inhibition around colonies of the 
fungus Penicillium notatum, the “contaminant” on his Staphylococcus aureus cultures, 
and later discovered that it was the small molecule metabolite penicillin that was killing 
the bacteria, a new era of chemistry and biology was ushered into being.6  From this 
point on, scientists would direct their attention to the world of microorganisms, both fungi 
and bacteria, in search of useful (and profitable) small molecules.  In 1944, Selman 
Waksman discovered streptomycin (8, Fig. 1.3) from the soil bacterium Streptomyces 
griseus, for the first time drawing the attention of academic and pharmaceutical interests  
Fig. 1.1    Structures of (1) the terpene “earthy” odorant geosmin, (2) the poppy derived 
alkaloid morphine, (3) the polyketide ionophore monensin and (4) the nonribosomal peptide 
antibiotic penicillin. 
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to this group of heretofore poorly understood saprobic, fungus-like, soil-dwelling 
bacteria.9  Belonging to the taxonomic order Actinomycetales, the genus Streptomyces 
has since become recognized as the single most prolific genus of drug-producing 
microorganisms. The chemistry and biology of this genus has been very thoroughly 
reviewed elsewhere. 7, 9-11 
The small molecule metabolites (e.g. 1-7) produced by bacteria such as the 
actinomycetes, generally referred to as natural products, are the hallmarks of bacterial 
secondary metabolism.  In contrast to primary metabolism, which refers to metabolic 
processes responsible for the production of “essential” molecules such as amino acids, 
fatty acids, nucleotides and sugars, secondary metabolism traditionally encompassed 
the production of “non-essential” small molecules, perhaps the most famous of which are 
the antibiotics.  The current understanding of the role of secondary metabolites in 
Fig. 1.2    Structures of fuscachelins A-C (5-7), nonribosomal peptides isolated from the 
thermophilic actinomycete Thermobifida fusca. 
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bacteria has brought into question the “non-essential” view of these molecules as they 
relate to the life cycle and complex community structures bacteria experience in their 
native environment.  The traditional definition thus reflects more accurately the biased 
view early researchers may have taken when only considering the pure, single-species 
conditions experienced in laboratory cultures.  With the selective pressures of the natural 
environment, secondary metabolites such as antibiotics could very well be viewed as 
essential to survival.  Nevertheless, there are important differences in the roles primary 
and secondary metabolites play in the life and survival of a microorganism.  Challis and 
Hopwood review this thoroughly.12  They point out that, unlike primary metabolites, 
which are found in all the kingdoms of life, share the same or similar metabolic pathways 
between organisms and, in general, reflect the common ancestry of all organisms, 
secondary metabolites are generally unique to a narrow taxonomic group (sometimes 
differing between subspecies), are produced under specific environmental conditions 
and reflect adaptation to a specific environment.  The chemical complexity and structural 
diversity of most natural products is an evolutionary reflection of the last point in 
particular.  
Nonribosomal Peptide Secondary Metabolites 
 Of the different classes of secondary metabolite natural products (see Fig. 1.1), 
the nonribosomal peptides (NRPs) comprise a large and ever-expanding group of 
molecules that, despite their incredible structural and functional diversity, share some 
very fundamental characteristics.13-17  NRPs can be defined generally as peptidic small 
molecules consisting of amino acid monomers (often 3-10 monomers, but with larger 
examples known) that are assembled by very large, multienzyme systems termed 
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nonribosomal peptides synthetases (NRPSs).18, 19  The sequence, amino acid content 
and molecule-specific chemical modifications of NRP natural products (phenotype) is 
often reflected in a molecule-specific gene cluster (genotype) that codes for the enzymes 
and proteins that control the biosynthesis and utilization of the small molecule.20  The 
genetic clustering of these systems reflects their evolutionary history and can be 
exploited by bioinformaticists in the discovery of new molecules.  NRPSs share 
important structural and mechanistic features that make them attractive targets for use 
as tools in chemoenzymatic syntheses.21, 22  The incorporation of nonproteinogenic 
amino acids into NRP scaffolds is one of the more striking hallmarks of this class of 
natural products, and their “just-in-time” biosynthesis is often directly linked with the 
gene clusters responsible for small molecule production.  Lastly, post-synthetic tailoring 
of peptide precursors is frequently required to yield the parent compound, and these 
important tailoring steps are executed by yet another suite of enzymes included in the 
NRP gene cluster.23, 24 Vancomycin (9), kutzneride 2 (10) and mycobactin (11, Fig. 1.3), 
three unique NRP natural products that require all of the biosynthetic components 
discussed above, illustrate how tremendous chemical diversity can be generated by 
systems that share, functionally if not always structurally, similar protein components.  
These aspects of NRP biosynthesis will be discussed in detail below. 
Secondary Metabolite Gene Clusters & Genome Mining 
 The successful biosynthesis and utilization of a NRP natural product requires the 
controlled and cooperative action of an impressively large suite of enzymes and 
proteins.  For example, NRP megasynthetases alone are comprised of polypeptide  
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chains that range from hundreds of kilodaltons to megadaltons in size.  Additionally, non- 
NRPS biosynthetic enzymes and regulatory, transport and resistance proteins may also 
be required.  As NRPs are usually only produced in response to specific environmental 
conditions, and because a relatively large amount of energy and resources is required 
for their expression and maintenance, it has proven evolutionarily useful to cluster the 
genetic elements of these systems into large, organized operons that can be placed 
under the control of a single promoter.11, 20  For example, the biosynthesis and utilization  
Fig. 1.3    Structures of (8) the antitubercular aminoglycoside antibiotic streptomycin and the 
nonribosomal peptide natural products (9) vancomycin, (10) kutzneride 2 and (11) mycobactin. 
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of the siderophore enterobactin (12), a ferric iron sequestering NRP made by enteric 
bacteria (E.coli and Salmonella sp.), is controlled by a gene cluster containing ORFs that 
code for the enterobactin NRPS, a set a genes that control the biosynthesis of the 
siderophore component 2,3-dihydroxybenzoic acid, transport proteins and a ferric-
enterobactin degrading enzyme (Fig. 1.4).25  The entire cluster is regulated by the well-
characterized Fur protein, which will only activate transcription under conditions of 
environmental iron stress.26, 27 
 The clustering of NRP-associated genes reflects more than an organism’s ability 
to conveniently control the expression of a set of related proteins.  It has been 
established that gene clusters are easily transmitted between organisms (inter and intra-
species) via the mechanisms of horizontal gene transfer.11, 20, 28  When one considers the 
function of many of the known bacterial secondary metabolites (antibiotics, 
Fig. 1.4    (A)  Structure of the NRP siderophore (12) enterobactin.  (B)  The enterobactin 
gene cluster contains (red) NRPS and NRPS-related enzymes, (green) enterobactin import 
and export proteins, (purple) a ferric-enterobactin degrading hydrolase and (blue) enzymes 
involved in the biosynthesis and incorporation of 2,3-dihydroxybenzoic acid. 
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antihelminthics, quorum-sensing molecules, etc…), the selective advantage imparted to 
the recipient of a complete natural product gene cluster becomes obvious.  As genomic 
sequence information continues to expand, so does our understanding of horizontal 
gene transfer mechanisms and the genome-wide context of secondary metabolite gene 
clusters.  This is especially the case for the actinomycetes, the prolific natural product 
producers that include species of the genus Streptomyces (vide supra).  It has been 
shown for the actinomycetes that secondary metabolite gene clusters are often located 
distal to genes that regulate primary metabolism on the bacterial chromosome.  In the 
case of the Streptomyces, all of which have a linear chromosome, this places the 
majority of secondary metabolite gene clusters on the exterior of the chromosome in 
“sub-telomeric” regions.9, 11  In many cases, the clusters are flanked by transposable 
genetic elements.  Gene clusters are found in plasmids (e.g. the Streptomyces coelicolor 
plasmids) and pathogenicity islands as well.  In addition, there are gene clusters that are 
found in numerous, unrelated species of bacteria, (e.g. the yersiniabactin NRP gene 
cluster is found in Yersinia pestis, the gram-negative human pathogen, and Salinispora 
tropica, a free-living aquatic actinomycete), pointing to horizontal gene transfer as the 
mechanism of genetic propagation.  The presence of multiple gene clusters in a given 
organism (many species of Streptomyces have more than 20) presents the opportunity 
for genetic editing of secondary metabolite gene clusters via gene translocations, 
deletions and duplications, both between and within gene clusters.  It is not surprising 
that natural product gene clusters change rapidly on the evolutionary time scale, often 
making their evolutionary history difficult to trace.  Nevertheless, examples of 
intermediate forms of gene clusters have been proposed.20  
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 In the twenty-first century “post-genomic” world, the field of bioinformatics has 
enlivened a renaissance of new small molecule discovery.  The bioinformaticist can 
employ computer-based diagnostics of genomic sequence data to find secondary 
metabolite gene clusters that code for as-yet uncharacterized natural products (so-called 
“orphan” or “cryptic” gene clusters).  This process, which has come to be known as 
genome mining, uses sequences of known secondary metabolic gene clusters to identify 
orphan gene clusters via sequence homology.  In the case of NRP gene clusters, it has 
become fairly straightforward to pinpoint the genes that code for NRP synthetases as 
their size and enzymatic components are unique and highly homologous, at least 
globally.  The aspects of an NRPS that result in the highly variable structures we find in 
the natural products are a result of finer details of the enzymatic system and do not 
detract from our overall ability to find orphan systems via sequence homology.  These 
details will be discussed below. 
 The process of genome mining has proven its worth as many new molecules, 
including the fuscachelins (Fig. 1.2), have been discovered using the results of genome 
mining to guide the isolation and structure elucidation process.8  Coelichelin (13), the 
orfamides (14) and erythrochelin (15) are but a few examples of no-longer-orphan NRP 
natural products that have recently been discovered via genome mining efforts (Fig. 
1.5).29-32 
Given the current state of genomic sequence availability and the rapid rate at 
which new sequencing data is being added to public databases, modest estimates 
suggest that the vast majority of biosynthetic secondary metabolite gene clusters, or  
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perhaps more importantly the products of these clusters, are yet to be discovered.7  
Thus, the current challenge is the development of bacterial growth methods that elicit the 
production of gene-cluster-specific small molecules.  These methods are likely to 
encompass non-traditional culture conditions and will often necessitate the use of 
specialized chemical or genetic tools relevant to a given system.  Genomic sequence 
data will no doubt play a central role in guiding the choice and application of these tools.  
Existing examples that embrace these approaches give credence to the power of the 
genome mining approach and have been thoroughly reviewed elsewhere.33   
Nonribosomal Peptide Biosynthesis 
Were a detailed understanding of NRP biosynthesis not thoroughly established 
previously, the genome mining approach to NRP natural product discovery would be 
Fig. 1.5    The NRP natural products (13) coelichelin (Streptomyces coelicolor), (14) 
orfamide A (Pseudomonas fluorescens) and (15) erythrochelin (Saccharopolyspora 
erythraea) were all discovered by a genome mining approach. 
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limited at best, if not impossible.  The structures and mechanisms of NRPS components 
are unique and are generally well established.  Structural and biochemical studies have 
laid the foundation upon which the relatively new field of bioinformatics is able to make 
accurate natural product structure predictions based solely on genomic sequence data.  
The salient features of NRP biosynthesis are outlined below, with an emphasis on the 
structural and mechanistic aspects that have made these systems amenable to 
bioinformatic analysis.   
 At the core of NRP biosynthesis is the nonribosomal peptide synthetase (NRPS).  
An NRPS is comprised of a long chain of individually folded enzymes that perform a 
specific function relating to the selection, activation, tethering, chemical modification of 
and covalent bond formation between NRP amino acid components.  These NRPS 
enzymatic building blocks, called domains, are organized into functional units termed 
modules, where any given module harbors a collection of domains that are responsible 
for selecting and chemically processing a single amino acid natural product component.  
A full NRPS peptide must contain one module, but most of the time will contain several, 
thus earning the title “megasynthetase”.   
In order to overcome the kinetic liability of linking together multiple diffusible 
amino acid and peptidic intermediates, NRPs are assembled on the NRPS via the 
covalent linkage of all amino acid building blocks and peptide intermediates.  A chemical 
tether, an 18 Å phosphopantetheine (PPT) “arm” derived from coenzyme A, presents its 
terminal thiol functionality as the point of covalent attachment via formation of an 
aminoacyl thioester (Fig. 1.6).  The apo-NRPS must be charged with the PPT prosthetic 
group by a dedicated phosphopantetheinyl transferase (PPTase) enzyme before it can 
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be biosynthetically functional.34, 35  The PPTase transfers the PPT group onto a 
conserved serine residue of the thiolation (T) domain (also referred to as the peptidyl 
carrier protein or PCP domain), a necessary component of every NRPS module.36  The 
holo-aminoacyl-NRPS then uses its PPT group as a molecular shuttle, transferring the 
amino acids and peptide intermediates between domain active sites for chemical 
processing and peptide assembly.  The thioester bond is exquisitely tuned to provide the 
thermodynamic driving force for peptide bond formation while at the same time 
furnishing a hydrolytically stable, albeit transient, chemical tether. 
In addition to a thiolation domain, each NRPS module must contain a domain 
dedicated to the selection and loading of amino acid substrates onto the PPT tether.  
This is the function of the adenylation (A) domain.37-40  The active site of an A domain is 
capable of selectively recognizing its amino acid substrate, activating its carboxyl group 
via adenylation (consuming an equivalent of ATP and releasing pyrophosphate), and 
tethering the amino acid adenylate to the terminal thiol of the PPT prosthetic group of its 
cognate T domain (releasing AMP) through the formation of an aminoacyl thioester.  The 
Fig. 1.6    Loading of the phosphopantetheinyl (PPT) tether onto an NRPS T domain through 
the action of a phosphopantetheinyl transferase (PPTase). 
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determination of A-domain selectivity is a critical tool in the bioinformatic analysis of 
orphan NRPS systems and will be discussed in more detail below. 
In order to assemble a peptide, an NRPS must have the ability to catalyze 
peptide bond formation.  This job is reserved for the condensation (C) domain.41, 42  The 
C-domain catalyzes the condensation of a “downstream” amine with an “upstream” 
aminoacyl thioester, tethered to the PPT arm of an adjacent module.  In a multimodular 
NRPS, the C-domain must act only when its upstream coupling partner is loaded with 
the appropriate amino acid or peptide substrate.  The ability of the C-domain to 
discriminate between processed and unprocessed substrate is central to the ability of a 
NRPS to produce full-length peptides, prevent the stalling and skipping of the NRPS 
machinery and avoid the production of truncated or incomplete NRP products. 
Once a mature peptide has been generated on an NRP megasynthetase, 
attachment to the terminal T domain must be severed to provide the completed product.  
The peptide cleavage reaction is catalyzed by the thioesterase (TE) domain.  Here, the 
completed product is passed from the final T domain, where it is tethered as a peptidyl-
thioester, to a conserved serine residue in the TE domain active site, generating a 
peptidyl-oxoester and liberating the PPT as a free thiol.  The peptide can then be 
cleaved from the NRPS via several possible routes.  In one common scenario, the 
peptide can be cleaved from the NRPS via hydrolysis, affording a carboxylic acid in the 
natural product.  In many cases, the TE-bound oxoester undergoes acyl transfer to a 
nucleophile found within the peptide product itself, affording a cyclized product.43-46  
Examples of these termination events are illustrated in detail below. 
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 The assembly of a peptide on a holo-aminoacyl-NRPS can be viewed as a three 
step process; initiation, chain elongation and termination.  Chain initiation and 
termination each require a dedicated NRPS module, while the number of elongation 
modules is highly variable and is often reflected in the size of the peptide product.  
Initiation modules, in general, contain an A and T domain.  The lack of a C domain 
reflects the fact that there is no upstream coupling partner.  On the contrary, elongation 
modules, implicit in their name, must contain a C domain in addition to A and T domains 
to catalyze peptide-elongating amide bond formation reactions.  The termination module 
contains a TE domain in addition to the C, A and T domains to catalyze cleavage of the 
mature peptide product.  It follows from the discussion above that in order to 
Fig. 1.7    Modular structure of an NRPS.  The condensation (C), adenylation (A), thiolation (T) 
and thioesterase (TE) domains are required, at minimum, for successful NRP synthesis. 
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successfully assemble a NRP natural product, an NRPS must contain initiation, 
elongation and termination modules that contain, at minimum, C, A, T and TE domains.  
This is illustrated schematically in Fig 1.7. 
The linear arrangement of NRPS protein domains and modules shown here  
often reflects the linear arrangement of the NRPS genes in a NRP biosynthetic gene 
cluster.  Thus, a bioinformaticist can frequently, if not always (vide infra), “read” a genetic 
sequence and know the N-to-C term order of the NRPS and thereby predict the structure 
of the resultant natural product once A-domain specificities have been determined.  N-to-
C term NRP natural product assembly has resulted in the “assembly line” concept of 
nonribosomal peptide biosynthesis, where amino acid and peptidyl intermediates can be 
envisioned moving along an NRP synthetase, undergoing chemical modification and 
chain elongation at modular weigh-stations.  The “colinearity” principal, which states that 
the sequence of NPRS modules dictates the identity, number and sequence of amino 
acid components in a NRP natural product, has sprung from the many cases where the 
N-to-C term NRPS sequence matches the sequence and composition of the natural 
product.13 The surfactin NRPS (Fig. 1.8) exemplifies the colinear NRP assembly 
paradigm. 
Note that the surfactin assembly line contains three NRPS megasynthetase 
enzymes, SrfA-C.  The initiation module of SrfA, contrary to the schematic in Fig. 1.7, 
contains a C-domain, which it uses to tether a C14 fatty acid (carrier protein not shown) 
to the N-term amino acid of surfactin (a glutamic acid residue).  Additionally, the 
termination module, SrfC, contains a macrolactone-forming TE domain that condenses  
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the β-hydroxyl functionality of the fatty acid onto the C-terminal TE bound leucine 
oxoester.43, 47 
Many of the first NRPS systems that were studied followed the principal of 
colinearity.  As more examples of NRP biosynthesis were discovered, it became 
apparent that the linear assembly of NRP natural products was not an overarching, 
universal principal and that the early systems were colinear simply by coincidence. For 
example, the nonribosomal peptide siderophore enterobactin is assembled by a NRPS 
assembly line that acts iteratively, where the constituent modules of the assembly line 
act more than once, albeit in a linear fashion, to assemble the enterobactin trimeric 2,3-
dihydroxybenzoylserine macrocycle (Fig. 1.9).48-50  The enterobactin synthetase is 
comprised of three biosynthetic enzymes, EntE, EntB and EntF.  EntE and B are stand-
Fig. 1.8    The surfactin NRPS.  The surfactin assembly line consists of three NRPS 
megasynthetase peptides, SrfA-C.  Here, the principal of colinearity is observed, where the N-
to-C term sequence of the NRPS dictates the N-to-C term sequence of the NRP product.  In 
this case, the surfactin termination module, SrfC, contains a macrolactone forming TE domain. 
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alone A and T domains dedicated to the selection, activation and covalent tethering of 
the 2,3-dihydroxybenzoic acid (DHB) moiety of enterobactin.  EntF is a unimodular 
NRPS that selects and tethers serine and trimerizes the DHB-Ser dipeptide in three 
iterative catalytic cycles. At the end of each cycle, a TE bound oxoester is formed. In the 
first cycle, DHB-Ser is transferred to the dedicated serine residue located in the TE 
active site.  After the second and third cycle, the DHB-Ser dipeptide is appended to the 
free β-hydroxyl of the serine residue from the previous dimerization cycle.  The DHB-Ser 
trimer is then cyclized by the TE domain to form the enterobactin macrotriolide.  Thus, in 
this case, a single NRPS module acts iteratively to assemble a hexameric natural 
product.  This stands in contrast to SrfA and B from the previous example, which also 
forms a hexapeptide but requires two, trimodular NRPS enzymes to do so.  In that case, 
the cell pays the cost of synthesizing and maintaining a much larger biosynthetic system 
for the payoff of greater monomer diversity (each module specifies a different amino 
acid).  In the case of enterobactin, which is one of the best iron chelating molecules 
known, the iterative NRPS allows for a smaller metabolic investment in biosynthetic 
machinery without sacrificing efficacy of the small molecule product.  
In the examples of surfactin and enterobactin, the NRPS assembles the peptide 
product in an N-to-C term fashion.  In some cases, an NRPS may synthesize its product 
in what is described simply as “nonlinear”.  Here, the rules of colinearity do not apply and 
the system may or may not be completely or partially iterative.  One of the most salient 
examples of this unique kind of NRP biosynthesis is the coelichelin synthetase (Fig. 
1.10).30  Coelichelin, a siderophore isolated from the archetypical actinomycete 
Streptomyces coelicolor, is the first NRP secondary metabolite predicted and isolated 
from S. coelicolor using a genome mining approach.  The coelichelin NRPS, CchH, is a  
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trimodular NRPS that, in one iteration, assembles the tripeptide (L-δ-N-formyl-δ-N-
hydroxy)ornithine-threonine-(L-δ-N-formyl-δ-N-hydroxy)ornithine and then, in a second, 
partial iteration, via the catalytic action of modules 1 and 3, ligates another equivalent of 
L-δ-N-formyl-δ-N-hydroxyornithine to the free α-amine of the tripeptide that is tethered to 
module 3.  In an unusual termination step, the free standing TE domain, CchJ, liberates 
the tetrapeptide from CchH via hydrolysis of the module 3-bound thioester. 
Bioinformaticists are still not able to predict examples such as these, where 
iterativity (either full or partial) and module skipping and repeating are major players in 
the biosynthesis of the natural product.  In fact, before coelichelin was isolated and 
structurally characterized, several incorrect bioinformatics-guided structure predictions  
Fig. 1.9    The enterobactin NRPS.  The enterobactin assembly line consists of a 2,3-
dihydroxybenzoic acid (DHB) activating A domain, EntE, a DHB tethering T domain, EntB and 
a unimodular NRPS, EntF.  EntE, B and F undergo three catalytic cycles before the EntF TE 
domain performs a macrolactonization to form the enterobactin DHB-Ser head-to-tail trimer. 
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were proposed and published (Fig. 1.11).12, 51  To date, genomic sequence data has not 
revealed the source of chemical information that dictates these events.  Further 
structural and biochemical studies are necessary before the predictive nature of 
bioinformatics can be applied to these systems.   
 
Fig. 1.10    Coelichelin synthetase.  CchH is a trimodular NRPS that assembles the coelichelin 
tetrapeptide.  In a display of partial iterativity, a third equivalent of L-δ-N-formyl-δ-N-
hydroxyornithine is added to the coelichelin tripeptide while module two is skipped entirely in 
the second iteration.  The unusual CchJ TE domain is free standing and catalyzes the 
hydrolytic cleavage of coelichelin from CchH. 
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The secondary metabolic pathways discussed above reflect what Mootz, 
Schwarzer and Marahiel eloquently and succinctly defined in 2002, namely that there 
are three kinds of NRP synthetases; Types A-C.13  A type A, or linear synthetase, 
assembles its peptide product following the colinearity rule (e.g. surfactin).  A type B, or 
iterative synthetase, also follows the rule of colinearity with the added caveat that it 
utilizes its modules in more than one catalytic cycle (e.g. enterobactin).  Lastly, a type C, 
or nonlinear synthetase, breaks the rule of colinearity (e.g. coelichelin).   
NRP Monomer Diversity 
 Ribosomally derived peptides and proteins are comprised of the twenty 
proteinogenic amino acids with almost no exceptions.  Nonribosomal peptide natural 
products, in contrast, have been shown to incorporate hundreds of different amino acid 
and carboxy acid monomers into their scaffolds (collectively).  In many cases, unique 
building blocks are generated in cis (i.e. by enzymes within the NRPS assembly line) by 
specialized protein domains that are incorporated, as required, into their respective 
Fig. 1.11    (A)  Two possible structures of coelichelin were predicted based solely on 
bioinformatic analysis of the coelichelin synthetase CchH.  (B)  Isolation and structure eluci-
dation of coelichelin revealed that the predicted structures were incorrect, exposing the 
inability of bioinformatics to detect module skipping and repeating. 
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NRPS module.  D-amino acids are common in nonribosomal peptides and are often 
generated in cis from their cognate L-amino acid by an epimerization (E) domain that 
inverts the stereochemistry at the amino acid α-carbon (e.g. SrfA, module 3 and CchH, 
module 2).  Other common in cis monomer modifications include methylation (MT), 
heterocyclization (Cy), oxidation (Ox) and reduction (Re) as illustrated in Fig. 1.12.16 
In many cases, nonproteinogenic NRP building blocks cannot be derived from 
simple, one step in cis transformations.  In these situations, the specialized component 
must be synthesized by a dedicated suite of enzymes, the genes of which are clustered 
along with the NRPS genes in the biosynthetic cluster.  2,3-dihydroxybenzoic acid is a 
component of many peptide siderophores (in the fuscachelins 5-7 and enterobactin 12) 
that is synthesized from the primary metabolite chorismate (Fig. 1.13A).25  N-δ-
hydroxyornithine is another common siderophore component (in fuscachelin 5-7, 
Fig. 1.12    Specialized NRPS domains in a hypothetical, trimodular NRPS for an R1-Ser-R3 
tripeptide.  In module 1, the N-terminus is methylated by a methyl transferase (MT) domain 
and the stereochemistry is inverted at Cα to give the D amino acid.  In module 2, serine is 
cyclized by a cyclization (Cy) domain and then oxidized by an oxidation domain (Ox) to 
afford the oxazole.  Finally, in module 3, a reductase (Re) domain is used to give the C-
terminal aldehyde (via hydride delivery from NADH).   
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mycobacitin 11, coelichelin 13 and erythrochelin 15) that is derived from the flavin 
catalyzed hydroxylation of the side chain amine of the amino acid ornithine (Fig. 
1.13B).52  3,5-dihydroxyphenylglycine, a critical player in the vancomycin (9) 
pharmacophore, is synthesized de novo by a polyketide synthase, a metal and cofactor 
free dioxygenase and an amino transferase (Fig. 1.13C).23  The hexahydropyrroloindole 
found in the kutznerides (10) is assembled from amino acid precursor 6,7-dichloro-L-
tryptophan, itself the product of tandem, FADH2 mediated chlorination reactions (Fig. 
1.13D).53  These examples illustrate some of the diverse chemistry employed to 
construct custom NRP building blocks, but countless other systems are known. 
Fig. 1.13    Nonproteinogenic NRP amino acids.  (A)  The 2,3-dihydroxybenzoyl moiety found 
in the catecholate class of siderophores is derived from the primary metabolite chorismate.  
(B)  L-N-5-hydroxyornithine, an important building block of the hydoxamate class of sidero-
phores, is derived from the amino acid ornithine via an FAD mediated oxidation.  (C)  The 
vancomycin component 3,5-dihydroxyphenylglycine is synthesized by an impressive suite of 
enzymes.  (D)  The kutzneride subunit 6,7-dichloro-L-tryptophan is synthesized from L-
tryptophan via two successive chlorination reactions. 
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NRP Tailoring Reactions 
Although the diversity of monomeric building blocks in nonribosomal peptides is 
expansive, evolution often employs an additional set of enzymes that “tailor” the 
completed assembly line product in yet another attempt to build up structural complexity.  
These so called tailoring enzymes can execute any number of functional group 
transformations and “decorating” reactions.  The biaryl crosslinks found in vancomycin 
(9) are formed in trans by P450 mediated oxidations (Fig. 1.14).23  These connections 
are critical in forming the “cup” shape of vancomycin, allowing it to affectively bind its D-
Ala-D-Ala target found on the ends of gram positive peptidoglycan polymers. 
The salmochelins are a group of siderophores and known virulence factors 
produced by enteric bacteria (Fig. 1.15).54  They are derived from the enterobactin 
Fig. 1.14    A series of in trans, P450 tailoring-enzyme-mediated oxidations form the biaryl 
crosslinks in vancomycin biosynthesis. 
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scaffold, but are modified by varying levels of glucosidation.  The sugar appendages 
increase the water solubility of the siderophore (enterobactin is surprisingly lipophilic) 
while at the same time decreasing their affinity for the binding pocket of siderocalin, the 
mammalian plasma protein that scavenges enterobactin.  
So, NRP tailoring enzymes, although at first glance peripheral to the main biosynthetic 
machinery (the NRPS), play absolutely essential roles in imparting upon a peptide those 
aspects that often make it unique.  Taken from a different perspective, it is often the 
complex structural features generated by the tailoring enzymes that present the greatest 
challenge to the synthetic chemist. 
Having considered the various aspects of NRP biosynthesis, we are now poised 
to examine a unique group of natural products, the siderophores, many (but not all) of 
which are assembled by NRP machinery.  We have already considered several in detail 
(enterobactin 12, coelichelin 13 and salmochelin 16).  NRP siderophores present ideal 
systems for teasing out the details of nonribosomal peptide biosynthesis, one of the 
most salient points being that they are produced under well defined growth conditions 
Fig. 1.15    The salmochelins are derived from enterobactin via C-glucosidation of the 2,3-
dihydroxybenzoyl rings. 
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that are easily generated in laboratory culture and that simple, sensitive and accurate 
chemical assays exist to test for their activity.  We will now shift our attention to this 
unique class of small molecule secondary metabolites.   
Siderophores 
 Virtually all organisms require the metal iron to live.  With its two accessible 
oxidation states, Fe2+ and Fe3+, iron stands as the archetypical biological transition metal 
catalyst, able to perform a vast array of essential redox chemistry.  From its role in 
electron transport in the respiratory chain to the action of the incredibly versatile 
cytochrome P450 and non-heme iron enzymes, the biocatalytic role of enzyme bound 
iron has inspired research in every field of the chemical sciences.  Its critical role in 
oxygen transport is perhaps one of the best-understood biochemical phenomena.  The 
centrality of iron in biological processes no doubt reflects its incredible natural 
abundance in the earth’s crust.27  Indeed, early organisms would have reaped the 
rewards of utilizing the rich chemistry of this metal.  Ironically, with the evolution of 
photosynthesis and the subsequent “poluting” of the atmosphere with its toxic byproduct, 
oxygen, the bioavailability of iron became drastically limited as the ferric oxidation state 
became the predominant oxidation state.  Ferric iron, unlike its ferrous counterpart, 
forms essentially insoluble iron(III) oxide complexes under non-acidic conditions, 
resulting in free iron(III) concentrations in the attomolar (10-18) range.  Those organisms 
that were able to selectively and efficiently solubilize and assimilate iron would have had 
a significant competitive advantage in their new aerobic environment.  The evolution of 
iron-scavenging small molecules, termed siderophores (from the Greek sidero  “iron” 
and phore “carrier”) has emerged as one of the major adaptations to result from 
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environmental iron limitation.  Additionally, in an oxygenic environment, free iron can 
readily react with oxygen, forming any number of poisonous reactive oxygen species 
(ROS).  Consequently, protein and small molecule antioxidant systems (e.g. superoxide 
dismutase, catalase, glutathione, mycothiol) and iron uptake and storage systems (e.g. 
(bacterio)ferritin, transferrin) are the evolutionary responses to the threat of ROS.  These 
topics continue to be of interest to scientists and medical professionals, but are outside 
the scope of this text.  The reader is directed to several recent reviews for more 
information.55-57 
Today, the struggle for iron sequestration is perhaps best illustrated in host-
pathogen relationships.58, 59  The human host goes to great lengths to maintain 
exceptionally low concentrations of free iron (e.g. free iron in plasma is on the order of 
10-24 M).  The proteins ferritin and transferrin are employed to control the levels of iron 
within cells and plasma, respectively.  Iron response proteins (IRPs) and iron response 
elements (IREs- mRNAs) have evolved to modulate intracellular iron levels at the 
transcriptional level.60  The synthesis of heme is tightly controlled in the mitochondrion.61  
As discussed above, the protein siderocalin is generated to scavenge bacterial 
siderophores in an effort to starve pathogens of iron.  These are but a few examples 
taken from the complex system of checks and balances employed by mammals to 
control the uptake, trafficking and utilization of iron.   
Considering the numerous iron regulatory defense mechanisms employed by 
host organisms, pathogens have had to become adept at hijacking the host iron pool.  
Some bacteria use cell surface proteins to directly import iron-bound host proteins.  
Hemophores, proteins that scavenge iron-loaded heme from cofactor containing host 
 28 
proteins, are also frequently used by gram-negative pathogens.62  Although effective, 
these systems require the presence of their specific iron-loaded target protein and are 
thus limited to host tissues or compartments where these sources are in abundant 
supply.58  The use of siderophores avoids this problem as they are capable to acquiring 
iron from all available sources.  Indeed, as has been noted above, siderophores are 
often important virulence factors (e.g. Salmochelin, E. coli, S. enterica; mycobactin, M. 
tuberculosis). 
For obvious reasons, siderophores from pathogenic bacteria have garnered a 
great deal of attention in the literature.  This does not detract from the importance of 
siderophores generated by free-living terrestrial and aquatic organisms.  Siderophore 
gene clusters have lent themselves nicely to the study of secondary metabolite 
evolution, especially with regard to their dispersal via horizontal gene transfer.11, 20  In 
fact, many siderophores produced by pathogens are likely derived from terrestrial 
organisms, acquired through horizontal gene transfer mechanisms (e.g yersiniabactin, 
vide supra).  The study of siderophoric iron acquisition by oceanic bacteria is, in some 
ways, still a burgeoning field.  A recent review by Sandy and Butler sheds light on the 
important advances in this arena, highlighting some of the truly unique structural, 
chemical and evolutionary discoveries that have resulted from studying these systems.62  
Siderophores play key roles in microbial community structure, interspecies 
communication and symbiosis.63-67  Indeed, the expanse of chemical and biological 
knowledge stemming from siderophore-centered research stands as a testament to the 
important role these molecules play in the lives of microorganisms in general. 
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 Traditionally, siderophores have been considered secondary metabolites.  As we 
have seen, they share biosynthetic and genetic traits with other classic examples of 
secondary metabolites (antibiotics, for example).  However (given the discussion above), 
it is clear that the successful production and use of a siderophore has a direct affect on 
the viability of its producing organism.  For example, an organism can survive in pure 
culture without the need to produce antibiotics, which were originally conceptualized as 
the “biological warfare” agents of the microbial world.  On the contrary, an organism may 
not be able to survive in pure culture under iron limited growth conditions without the use 
of a siderophore.  Modern genetics has shed more light on this point.  Take, for example, 
the genomes of the actinomycetes S coelicolor, S. griseus and S. avermitilis.  All of 
these organisms produce the siderophore desferrioxamine (17, Fig. 1.16).  The genes 
for this “secondary metabolite” are located at the center of the genome of all three 
species, clustered with the genes for primary metabolism.  The genes exhibit synteny 
between all three organisms and are read in the same direction.   
Fig. 1.16    The siderophore desferrioxamine B (17) is produced by the actinomycetes S. 
avermitillis, S. coelicolor, and S. griseus.  The desferrioxamine gene cluster exhibits synteny on 
all three bacterial chromosomes and is read in the same direction, providing a genetic challenge 
to the traditional definition of “secondary” metabolism. 
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This stands in stark contrast to the rest of the secondary metabolite gene clusters, which 
are located on the arms of the chromosome in subtelomeric regions.  These regions 
tend to contain transposable genetic elements, are much more likely to undergo 
recombination and translocation events and tend to be the site of integration of 
Streptomyces plasmids.11  Similarly, as will be discussed in chapter 2 of this text, the 
fuscachelins are the only NRP natural products to be found in the entire genome of T. 
fusca, again calling into question the concept of “nonessentiality” regarding secondary 
metabolite natural products.8, 68  Nett, Ikeda and Moore have provided a comprehensive 
review regarding the genomic basis of secondary metabolite biosynthesis genes in 
actinomycetes.11  Walsh and Fischbach reexamine the concept of “secondary” 
metabolism in another recent review.14 
Siderophore Iron Trafficking in Bacteria 
 Once a siderophore has been synthesized, its fate is highly controlled by a 
system of pathway-specific transport proteins (Fig. 1.17).  In gram-positive bacteria, this 
consists mainly of transmembrane active transport proteins that regulate the efflux and 
uptake of the apo- and ferrisiderophore complex, respectively.  The scheme is 
somewhat more complex in gram-negative microorganisms whose inner and outer 
membranes present a more formidable barrier to small molecule transport.27, 57, 58, 69  In 
this case, the apo-siderophore is actively transported across both the inner and outer 
membrane.70, 71  A two-step process is pictured in Fig. 1.17, but different organisms may 
employ different efflux systems.  Thus, in some cases, a single, energy consuming step 
requiring complex, periplasm-spanning protein complexes are utilized.  Once iron-
charged, the holo-siderophore binds to a membrane spanning β-barrel transport protein. 
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The siderophore-bound status is then communicated to an inner-membrane TonB 
(Transport of iron) complex, which couples energy from the proton motive force with the 
active uptake of the siderophore-iron complex.72  Once released to the periplasm, a 
periplasmic binding protein transports the siderophore to an inner member import protein 
(usually an ABC transporter) that delivers the holo-siderophore to the cytoplasm.  In both 
gram-positive and gram-negative bacteria, iron is removed from the ferrisiderophore 
complex via reduction of the metal and/or destruction of the siderophore ligand.  The 
metal is then passed on to intracellular iron pathways for storage or utilization.73, 74   
The tight control of siderophore utilization reflects the importance of controlled 
iron trafficking.  Bacteria generally maintain micromolar (10-6) intracellular iron 
concentrations under environmental conditions, where the concentration of free iron is 
orders of magnitude less.  Because the presence of free iron in the cytosol is potentially 
Fig. 1.17    Siderophore export and import systems in (A) gram-positive and (B) gram-negative 
bacteria.  Show in green; ATP-transporters, red; β-barrel pore proteins, blue; TonB complex 
proteins and orange; periplasmic ferrisiderophore transport protein. 
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dangerous (e.g. production of poisonous ROS), the active import of the metal must be 
scrupulously controlled. On the other hand, accidental import of a desferrisiderophore 
would be a waste of time and cellular resources.  Thus, sophisticated iron transport and 
utilization systems have been evolved to handle this challenge.  Not surprisingly, the 
processes discussed above are coupled to transcriptional regulatory mechanisms.73, 74 
Iron Chelation 
 An effective siderophore needs to bind iron selectively and with very high affinity.  
Ferric iron is a hard lewis acid, so it is not surprising that most siderophores employ 
hard, lewis basic oxide ligands to bind their metal target.  Ferric oxide complexes tend to 
have remarkable kinetic stability as well, resulting from strong coulombic interactions 
between the oxygenic ligand and the metal center.  X-ray crystal structures of iron 
loaded siderophores have revealed that oxygen donor groups nicely satisfy the 
geometric requirements of the iron(III) coordination sphere, which is a major factor in 
metal binding selectivity.75  We have examined the examples of enterobactin and 
coelichelin in detail already.  These molecules use catecholate and hydroxamate 
(respectively) functionality for metal chelation.  Other common chelating groups include 
α-hydroxycarboxylates (e.g. petrobactin, 18) and heterocycles (e.g. yersiniabactin, 19) 
derived from serine, threonine and cysteine (Fig. 1.18).   
 The thermodynamic stability of a siderophore is reflected in its formation constant 
Kf (often referred to as βmlh) for the equilibrium in Eq. 1: 
Eq. 1     mM + lL + hH    MmLlHh 
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where M is metal (Fe3+), L is ligand (siderophore) and H is proton.  Formation constants 
are, by definition, reported as β110 for hexadentatic siderophores.  (Note: enterobactin 
has the highest reported β110 for ferric iron of any compound ever found, with β110 = 
1049).  Implicit in Eq. 1 is the dependence of β110 on the acid/base (pKa) equilibria 
between L and H, where protons compete with the metal for ligand binding.  Consider 
the pKa values for catechols  (6.5-8.0 and 11.5), hydroxamates (8.0-9.0) and 
carboxylates (3.5-5.0).  It follows that for organisms living in acidic environments, the 
carboxylate class of siderophores would be most effective at metal binding as they are 
most likely to be deprotonated at lower values of pH (as is the case for many fungi).  On 
the contrary, a catecholate siderophore would be appropriate for a pathogen (e.g. E. coli 
– enterobactin) that lives at physiological pH (7.4).  For these reasons, the β110 value is 
not often considered a realistic reflection of iron binding affinity under “real world” 
circumstances.  (An added caveat is that, in some cases, the high pH values required to 
measure β110 result in ligand decomposition!)  Thus, an alternative method of measuring 
Fig. 1.18    The citrate based siderophore petrobactin (18) utilizes an α-hydroxycarboxylate 
group, in addition to its unique 3,4-dihydroxybenzoyl moieties to chelate iron.  Yersiniabactin 
(19) employs a series of thiazoline and thiazolidine rings for the same purpose. 
 34 
iron binding affinity has been developed, whereby the pFe of free iron in the presence of 
siderophore ligand is measured in a pH dependent manner (Eq. 2): 
Eq. 2     pFe = -log[Fe3+]f    
(Under conditions where: [Fe3+]t = 10-6 M, [L]t = 10-5 M, pH = 7.4) 
where [Fe3+]f is the free iron concentration at equilibrium, [Fe3+]t is total iron concentration 
and [L]t total ligand concentration.  Thus, the value of pFe better reflects the ability of 
siderophores to compete for metal under environmentally relevant conditions.27 
 Ligand denticity and preorganization, in addition to pKa, greatly impact the 
stability of a ferrisiderophore complex.  One would imagine that to satisfy the six 
coordination sites of iron(III) and achieve the greatest chelate effect, a successful 
siderophore would coordinate iron in a hexadentatic fashion, forming a 1:1 ligand:metal, 
octahedral complex.  This is indeed the case most of the time.  However, 1:2, 1:3 and 
2:3 metal:ligand complexes are known as well.  Further, as the chelate effect results 
from an increase in ΔS upon complex formation, it stands to reason that for large, 
confomationally flexible molecules such as peptides, preorganization of the metal-
binding scaffold stands to help maximize this effect.  As with other peptide natural 
products, macrocyclization strategies are thought to lock many siderophores into a 
favorable metal-binding conformation.  Not surprisingly, this has been proven for 
enterobactin, where hydrolysis of the macrolactone core results in decreased iron 
binding affinity.  This is reflected in the natural system, where a cytosolic esterase (Fes – 
ferric enterobactin esterase) is used to hydrolyze the enterobactin macrocycle and 
release iron.25  See Fig. 1.19 for illustrations of the examples discussed above.   
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Since siderophore-iron complexes tend to be so stable (i.e. iron binding is 
irreversible), iron removal is enzymatically controlled.  The Fes system found in E. coli, 
where the ligand is destroyed to liberate the metal, represents one of two iron release 
mechanisms.  More commonly, iron removal is driven by the enzymatic reduction of the 
metal center from Fe3+ to Fe2+.  Ferrous iron is a much softer lewis acid than ferric iron.  
The dramatic decrease in coulombic attraction between metal and ligand also serves to 
destabilize the ferrous complex.  Lastly, the greatly decreased ratio of charge to ionic 
radius of the ferrous state cannot, in general, accommodate siderophore ligands.  Metal 
reduction is, in most cases, catalyzed by flavin containing reductases.  Once the metal is 
liberated, it is passed to intracellular iron storage proteins or incorporated into iron 
containing enzymes.57, 73 
Fig. 1.19    Siderophores can form several kinds of chelation complexes with varying levels of 
denticity.  (A)  Coelichelin is a hexadentate ligand that produces a 1:1 ligand:metal, octahedral 
complex.  (B-C)  Pyochelin is capable of froming both 2:1 and 3:2 metal:ligand chelates.  (D)  
2,3-dihydroxybenzoic acid can act as a bidentate siderophore that produces a 3:1 metal:ligand 
complex.  (E)  The triserine macrolactone of enterobactin predisposes the siderophore for 
complex formation. 
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The Chemical Synthesis of Siderophores 
 There are hundreds of known siderophores.  Taken together, they exhibit a truly 
remarkable range of structural complexity and chemical diversity.  Coupled with their 
biological importance, it should come as no surprise that siderophores have garnered a 
great deal of interest from the synthetic community.  Countless siderophores have been 
the subject of total syntheses, used as platforms to develop new synthetic chemistry. 
They have attracted the attention of the medicinal chemistry community as well.  As 
siderophores are central to pathogen viability, proteins involved in siderophore 
biosynthesis and transport are attractive drug targets.  In some circumstances, 
siderophores themselves have proven to be useful drugs.  We will explore these topics 
briefly below. 
 Siderophores have inspired numerous total syntheses.76  As is often the case, 
the desire to produce useful quantities of a compound for laboratory experiments is a 
driving force for synthetic endeavors.  If planned properly, the synthetic route can serve 
as a platform to demonstrate the utility of new chemistry.  This was the case in 1977, 
when Corey and Bhattacharyya completed the first total synthesis of enterobactin.77  In 
this context, they were able to successfully employ the Corey-Nicolaou 
macrolactonization, which had been developed only a few years prior and which has 
since been applied in countless syntheses of natural product macrocycles.78  In the key 
complexity building step, they were able to elaborate triserine precursor 20 to the 
enterobactin lactone (22) using Brunelle’s modification of the Corey-Nicolaou reagent, 
2,2´(4-t-butyl-1-isopropylimidazolyl) disulfide (21), and triphenylphosphine (Fig. 1.20). 
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Other important total syntheses include the preparation of desferrioxamine B by 
Bergeron and Pegram, and that of petrobactin, also by Bergeron and coworkers.79, 80  
Desferrioxamine is the active agent in the drug Desferal®, used for treatment of iron 
overload disorders.  Petrobactin is a virulence factor produced by Bacillus anthracis and 
is also utilized by the hydrocarbon degrading bacterium Marinobacter 
hydrocarbonoclasticus, making it of interest to both the medical and environmental 
communities.  Its original structure elucidation included the typical 2,3-dihydroxybenzoyl-
moeity as an iron chelating agent.  Via total synthesis, it was proven that petrobactin 
actually contains the unique 3,4-dihydroxybenzoyl functionality instead (see Fig. 1.18).   
The synthetic assembly of hydroxamic acids, the hallmark of the hydroxamate 
class of siderophores, often plays a central role in the synthesis of this class of 
siderophore.  Thus, it is not surprising that there are multiple synthetic routes available 
that provide access to this important iron-chelating scaffold.  In their synthesis of 
acinetoferrin (23), Wang and Phanstiel directly construct the N-O bond via treatment of 
3-(tert-butoxycarbonylamino)propylamine (24) with benzoyl peroxide (BPO), providing 
the O-benzoyl protected N-oxide (25).81, 82  Subsequent acylation affords the completed 
hydroxamic acid product (26, Fig. 1.21A).  In a slightly different approach, Miller and 
coworkers prepare O-benzyl protected hydroxamates (28) in one step by treating alkyl 
Fig. 1.20    Corey and Bhattacharyya employed the disulfide (21) to perform the macrolacton-
ization of triserine 20 to afford the enterobactin core 22.   
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bromides (27) with N-acyl-O-benzylhydroxylamines (29, Fig. 1.21B).  This method has 
been applied to several total syntheses that include the preparation of aerobactin (30) 
and mycobactin, among others.83-86   
 
 
Fig. 1.21    The syntheses of (A) acinetoferrin (23) and (B) aerobactin (30) employ different 
routes for the construction of the hydroxyornithine iron-chelating functionality. 
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In some cases, it is advantageous to directly prepare N-δ-hydroxyornithine (31) 
or N-ε-hydroxylysine for direct incorporation into siderophore scaffolds or for use in 
biochemical experiments.  Lin and Miller established a facile route to these compounds 
by employing an “indirect oxidation” method (Fig. 1.22) in the synthesis of siderophore-
biotin conjugates (32).87  The naturally occurring “trojan horse” antibiotics inspired the 
synthesis of these compounds.  Consisting of a siderophore covalently linked to a 
cytotoxic small molecule or peptide, the target microorganism uses its siderophore 
uptake system to import the “siderophore”.  Upon delivery to the cytoplasm, the drug-
siderophore linkage is cleaved, liberating the antibiotic.  The albomycins (33) and 
Microcin E492 (34) are naturally occurring siderophore-antibiotic conjugates that are 
produced by gram-positive organisms, many of the genus Streptomyces (Fig. 1.23).54 
 Because pathogens so frequently produce siderophores via NRPS directed 
biosynthesis, these systems have become attractive antibacterial drug targets.  In 
particular, inhibition of the salicylic acid activating A-domain in mycobactin biosynthesis  
Fig. 1.22    Lin and Miller provide a direct route to N-δ-hydroxyornithine in their synthesis of 
siderophore-biotin conjugates 
 40 
(M. tuberculosis) can be achieved using a 5´-O-[(N-salicyl)sulfamoyl]adenosine (35), a 
non-hydrolyzable salicylic acid adenylate mimic (36) (Fig. 1.24).88, 89  This plays off of the 
common use of 5´-O-[(N-acyl)sulfamoyl]adenosines as tools to study A domain 
chemistry in NRP biosynthesis.90 
 
 
 
 
Fig. 1.23    The albomycins (33) and microcin E492 (34) are naturally occurring siderophore-
antibiotic conjugates that utilize the siderophore uptake systems of target organisms to deliver 
the “trojan horse” antibiotic to the cytoplasm.  
Fig. 1.24    5´-O-[(N-salicyl)sulfamoyl]adenosine 35 has been shown to inhibit the salicylic acid 
activating A-domain of M. tuberculosis.  This type of sulfamoyl adenosine inhibitor is a 
nonhydrolyzable mimic of the naturally produced acyl adenylates (e.g. 36) that are generated in 
NRPS A-domains. 
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Perspective 
 We have, at this point, explored the details of bacterial secondary metabolism, 
placing an emphasis on NRP natural products.  In conjunction with our examination of 
the biology and chemistry of siderophores, we are poised to discuss the isolation, 
structural characterization and chemical synthesis of the fuscachelins.  Throughout the 
remainder of this text, it will be revealed how the combined knowledge of the topics 
above can be employed to facilitate our discovery and understanding of novel small 
molecules.  As the chemical, biological and computer sciences continue to converge, it 
is entirely possible that science will experience a second “golden age” of natural product 
discovery.  Indeed, as we have now entered the “post-genomic” era, this renaissance 
has perhaps already begun. 
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Chapter 2 
 
The Isolation and Structure Elucidation of 
the Fuscachelins, Nonribosomal Peptide 
Siderophores from Thermobifida fusca 
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Preface 
 The history of mankind’s relationship with naturally occurring small molecules is 
traceable to the earliest civilizations.  Our forebears document the medicinal use of 
countless extracts or preparations derived from natural sources.  Indeed, ancient 
Mesopotamian and Egyptian texts from as long ago as 2800 and 1550 B.C.E have been 
recovered that describe, among other things, the medicinal use of Papaver somniferum 
(morphine – discussed in chapter 1) and Aloe vera.  It was not until 1826 that Merck 
made morphine available, in its pure form, as the first commercial drug.  Further, it 
required the dawn of the modern chemical sciences in the 19th and 20th centuries for 
scientists to be able to purify and structurally characterize the active ingredients of 
natural extracts, thereby providing a connection between chemical composition and 
biological function.  The “golden age” of antibiotic discovery of the 1940’s and 50’s (as 
discussed in chapter 1) may perhaps be viewed then, as a pinnacle of human 
achievement regarding the use of natural products as medicinal agents.  Ironically, in the 
1990’s, advances in technology and synthetic chemistry lead industry away from further 
development of natural product based drugs due to the wholesale embrace of 
combinatorial chemistry.  The payoff from this investment has so far proven to be less 
than was hoped for.  Thus, we now see a return of academic and industrial interest to 
the field of natural product chemistry.  Perhaps the single biggest player to catalyze this 
change of zeitgeist is the ability of modern biology to quickly and accurately sequence 
entire genomes.  As a result, public databases are now bursting with genomic data that 
can be used to unearth heretofore undiscovered, and potentially useful (and profitable) 
small molecules.  Indeed, the instance of Fleming innocently (or perhaps, sloppily) 
“stumbling” upon penicillin continues to stand as a testament and metaphor to the 
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importance of continued natural products discovery, and the current confluence of 
modern technology, chemistry and biology foreshadows a promising future for these 
ambitious scientific endeavors.1-7 
Introduction 
 Bacterial genera belonging to the actinomycetes, in particular the Streptomyces, 
have proven to be some of the most prolific producers of small molecule secondary 
metabolites ever studied.8, 9  With the rapid expansion of genomic sequence data over 
the last decade, the secondary metabolic potential of previously untapped microbial 
genera have become readily accessible targets for genome mining initiatives.5, 10-12  The 
soil dwelling, thermophilic actinomycete Thermobifida fusca (previously 
Thermomonospora fusca) presented an interesting prospect for such an effort.13  The 
secondary metabolic output of thermophiles is, at best, a burgeoning field, with very few 
examples of natural products known from this important and unique class of 
microorganisms.14  Additionally, T. fusca has long been of interest to the energy and 
environmental communities due to its well-established ability to act as a degrader of 
plant cell wall polysaccharides, including cellulose.15-17  The possibility of isolating and 
developing enzyme catalysts capable of efficiently degrading these biological polymers 
could reap financial and political dividends for industrial and national interests.  The 
possibility of a thermostable catalyst is thus particularly appealing.  Perhaps less 
prevalent in the literature, but nevertheless important, is the pathogenic role this 
organism plays as a causative agent of farmers lung, a condition resulting from 
inhalation of dry, airborne spores of the organism.   
Thus, when the genome of T. fusca was completed in 2007, we viewed it as a 
very attractive, and untapped, source of secondary metabolites upon which new 
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research could be built form the ground up.18  In the interest of studying the (very large, 
complex) enzymatic machinery involved in nonribosomal peptide (NRP) secondary 
metabolism, the ability to study a thermostable system presented both pragmatic and 
scientific benefits.  Namely, thermophilc proteins tend to exhibit enhanced stability and a 
propensity to crystallize.19-21  Structural and chemical characterization of one of these 
systems would not only reveal mechanistic details of NRP biosynthesis, but would also 
allow for comparison to mesophilic enzymes.  We also felt that, as a thermophile, the 
likelihood of discovering a secondary metabolite with novel structural characteristics was 
likely, as this group of microorganisms essentially presented a secondary metabolic 
tabula rasa.  We were pleased then to discover that the genome of T. fusca contained 
one NRP gene cluster that contained the hallmarks of siderophore biosynthesis.  Efforts 
to isolate the small molecule product of this gene cluster resulted in the discovery of the 
fuscachelins, a group of structurally novel NRP siderophores.22  The isolation and 
structure elucidation of these T. fusca secondary metabolites is discussed below.  
 
Bioinformatic Analysis of the Fuscachelin Biosynthetic Gene Cluster 
Bioinformatic analysis of the T. fusca genome revealed a gene cluster that 
corresponded to a multi-modular nonribosomal peptide (NRP) synthetase secondary 
metabolite biosynthetic pathway (Fig. 2.1).  Three NRP synthetase genes, designated 
fscGHI, are contiguous in the cluster and correspond to five peptide extension modules.  
The first gene, fscG encodes a 390 kDa protein comprised of three NRP synthetase 
modules, each containing the core elongation domains: condensation (C), adenylation 
(A) and thiolation (T).  The first module contains a predicted epimerization (E) domain, 
suggesting that the stereochemistry of the corresponding amino acid in the product is of  
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the D-configuration.  The second gene, fscH, contains a single elongation module and is 
followed by a gene for the termination module, FscI, which contains a C-terminal 
thioesterase (TE) domain.  Upstream of fscGHI are genes with sequence homology to 
characterized 2,3-dihydroxybenzoic acid (DHB) biosynthetic genes.  FscA, FscB and 
FscD are homologous to the well-characterized catecholate biosynthetic enzymes: 
isochorismate synthase, isochorismatase and 2,3-dihydro-DHB dehydrogenase.23-25  An 
adenylation domain (FscC) with predicted specificity for DHB and a dedicated aryl-
carrier protein (FscF) are present as stand-alone domains to incorporate DHB as the 
starter building block.  Additional proximal genes are present that are homologous to 
genes traditionally associated with siderophore production and utilization.  These include  
 
Fig. 2.1    The fuscachelin biosynthetic gene cluster.  fscA-D and fscF are involved in 2,3-
dihydroxybenzoic acid biosynthesis and NRP incorporation.  fscE generates N-δ-hydroxy-
ornithine.  fscG-I code for the NRPS assembly line.  Genes flanking the biosynthetic machinery 
are implicated in siderophore utilization and transport. 
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an L-N-δ-hydroxyornithine (L-HOOrn) hydroxylase (FscE), membrane proteins for 
siderophore export and uptake and a ferric iron reductase.   
The amino acid specificity of the individual modules can be predicted using 
methodology that compares active site residues of known NRP synthetase A domains 
(Fig. 2.2A-B).26-28  The specificity of the first module of FscG did not correspond 
convincingly to any characterized domains, but suggested activation of a basic amino 
Fig. 2.2    (A)  The NRP synthetase enzymes that direct fuscachelin biosynthesis.  T domains 
are pictured loaded with the amino acids predicted from A-domain homology.  For module 
FscG1, a definitive prediction could not immediately be made, but sequence homology 
suggested an amino acid with a basic side chain, denoted as R.   The predicted structure of 
the peptide natural product is highlighted in red.  (B)  Amino acid specificity conferring active 
site residues of fuscachelin synthetase A domains (bold) are aligned with homologous A 
domains, allowing for peptide structure prediction. 
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acid.  The second and third modules of FscG are highly similar to each other (~85% 
identity over the adenylation domains) and both are predicted to activate glycine. 
Analysis of FscH and FscI suggest activation of L-serine and L-HOOrn respectively. 
Based on this analysis, the peptide product can be predicted as a pentapeptide, N-
capped with DHB, a structural architecture unlike any characterized siderophore (Fig 
2.2A). 
Isolation and Structure Elucidation of the Fuscachelins 
To resolve the structure of the T. fusca siderophore, the natural product was 
isolated from the producing bacterium and characterized using NMR and mass 
spectrometry.  T. fusca was grown in iron-depleted Hägerdal media at 55 ºC and the 
siderophore was extracted from pelleted cells using methanol.29  Siderophore activity 
was monitored throughout production and purification using the chromazurol S (CAS) 
assay of Schwyn and Neilands.30  In addition, fractionation by HPLC was monitored by 
absorption at 320 nm, the characteristic λmax of the predicted DHB functionality.  Four 
separate peaks were isolated from the preparation (Fig. 2.3A).  A minor peak, with the 
longest retention time, was the free acid 2,3-DHB as determined by NMR analysis.  A  
Fig. 2.3    (A)  HPLC Purification of the fuscachelins (320 nm).  (B)  Structures of the 
fuscachelins. 
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major peak (corresponding to fuscachelin B) was further purified by reverse phase 
chromatography and the structure determined.  1H, TOCSY and COSY experiments 
established the amino acid content of the peptide by identifying the individual amino acid 
spin systems: Arg, Gly, Ser, HOOrn in addition to DHB.  Unexpectedly, 13C and 15N 
gHMBC experiments to confirm the amino acid connectivity revealed a heterodimeric 
peptide with the sequence DHB-Arg-Gly-Gly-Ser-HOOrn-Gly-Gly-Arg-DHB (Fig. 2.3B, 
Table 1).  The mass of the isolated product supports this structure with a measured 
Table 1.    1H and 13C NMR Spectral Data for Fuscachelin B 
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exact m/z of 1048.4448 ([M+H]+, calculated 1048.4448) and a molecular formula of 
C42H62N15O17.  Close examination of the 1H NMR spectra reflect a heterodimeric 
structure. For example, the integration of the amide and α-C protons is 4:2:1:1, 
Gly:Arg:Ser:HOOrn and fine double signals are evident in the asymmetric halves of the 
molecule (for example the protons of Arg and DHB).  To confirm the NMR structural 
assignment, MALDI TOF-TOF fragmentation (Fig. 2.4) was performed and all fragments 
are consistent with the predicted structure. The determination of amino acid chirality was 
conducted using Marfey’s method, which indicated the presence of Gly, D-Arg, L-Ser 
and L-HOOrn in a ~ 4:2:1:1 ratio based on peak integration.31   
An additional chromatographic peak from the T. fusca preparation, eluting just 
prior to fuscachelin B, exhibited very similar NMR spectra to fuscachelin B.  The 
measured m/z of this distinct product was 1047.4614 ([M+H]+, calculated 1047.4608, 
C42H63N16O16) corresponding to a change to an NH versus an O in fuscachelin B.  
Inspection of the 1H NMR and mass spectral fragmentation data revealed that this 
difference was localized at the HOOrn residue and additional NMR experiments, in 
particular 1H/15N gHSQC, are consistent with an α-carboxamide structure (termed 
fuscachelin C) as shown in Fig. 2.3B.  
Fig. 2.4    MALDI TOF-TOF fragmentation study of the fuscachelin B peptide supported the 
structure determined via NMR spectroscopy. 
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A third CAS-positive fraction (fuscachelin A) was evident in the chromatographic 
separation (Fig. 2.3A).  This fraction was unstable during the process of purification and 
appeared to slowly decompose to fuscachelin B.  The mass of this peak is 18.0103 Da 
(exact mass of H2O = 18.0106) less than fuscachelin B ([M+H]+, m/z predicted: 
1030.4342, m/z observed: 1030.4344), suggesting a hydration/dehydration process.  
Aspects of the NMR spectra of fuscachelin A were similar to those described for 
fuscachelin B, with the D-Arg and Gly signals remaining largely the same.  There were, 
however, distinct differences in the L-HOOrn, L-Ser and DHB signals.  In particular, the 
diastereotopic β-hydrogens of serine were shifted to 4.48 and 4.36 ppm (compared to 
the 3.77 ppm multiplet in fuscachelin B), suggesting the presence of a seryl ester.  In 
addition, shifts in the L-HOOrn side chain δ-protons signals were pronounced. These 
differences suggested a substantial change in the chemical environment of these two, 
centrally located amino acids, in the fuscachelin peptide.  Furthermore, this change was 
capable of being communicated to the DHB moiety in the extremities of the molecule, as 
is evidenced by the increased complexity of the splitting patterns and broadened peaks 
of the aromatic protons.  Interestingly, over time, upon standing at ambient temperature 
in unbuffered D2O, these changes in proton signals began to disappear as signals for 
fuscachelin B concurrently grew into the spectrum.  These observations, in concert with 
the observed mass difference, suggested the presence of a macrolactone involving the 
serine sidechain and the α-carboxyl of L-HOOrn (Fig. 2.3B).  The unusual 10-membered 
cyclodepsipeptide core structure in fuscachelin A was supported by additional NMR-
based measurements.   
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Chemical evidence to support the presence of a macrolactone was established 
as well.  The hydrolysis of the lactone was observed by submitting fuscachelin A to 
basic, hydrolytic conditions (Fig. 2.5).  Monitored by HPLC, the results show the 
conversion of fuscachelin A to fuscachelin B.  Further, if fuscachelin B is treated with the 
coupling reagents PyBOP and DMAP under dilute conditions in N,N-dimethyformamide, 
conversion of fuscachelin B to A is observed (Fig. 2.5).  As discussed below, the 
fuscachelin A macrolactone is the probable biosynthetic product of the T. fusca, fsc gene 
cluster.  
Siderophore production and utilization is dependent on cellular responses to iron 
in the environment.  The concentration of iron in the growth media affects the expression 
of bacterial siderophore biosynthetic genes.  To provide evidence that the fuscachelins 
are the biologically-relevant siderophore for T. fusca, the bacteria were grown in 
Hägerdal media with and without iron and the production of fuscachelin was monitored 
Fig. 2.5    HPLC traces showing the degradation of fuscachelin A to B upon treatment with 
base and the PyBOP mediated lactonization of fuscachelin B to A. 
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by HPLC analysis.  As predicted, the presence of iron suppressed fuscachelin 
production.  In addition, a ferric-fuscachelin B complex was prepared in the presence of 
FeCl3 and analyzed by mass spectrometry ([FuscB-2H++Fe3+]+, C42H59N15O17Fe+, pred. 
m/z 1101.3557, obs. 1101.3600).  Lastly, energy minimization of fuscachelin A results in 
a structure where the two catechols are in proximity to the central hydroxamate and 
modeling of a metal chelate is easily accommodated (Fig. 2.6). 
Cloning, Purification and Biochemical Characterization of FscI 
In order to provide supporting evidence that the fsc genes are responsible for the 
in vivo production of the fuscachelins in T. fusca, the NRPS termination module, FscI, 
was characterized in vitro.  The 4.0 kb gene for fscI was cloned from T. fusca genomic 
DNA into an E. coli expression vector using PCR-based methods.  The four-domain 
protein was overexpressed in E. coli to high levels and purified to homogeneity as 
Fig. 2.6    MMFF equilibrium conformer of ferric fuscachelin A.   
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judged by SDS-PAGE analysis (Fig. 2.7A).  The amino acid specificity of the module 
was determined using the pyrophosphate exchange assay of adenylation domain 
function.  L-HOOrn was chemically synthesized using published protocols from N-Boc-L-
ornithine.32  This predicted amino acid was assayed along with the 20 proteinogenic 
amino acids and L-ornithine.  The results show a significant preference for L-HOOrn with 
the next best amino acid substrate being the isosteric L-lysine (Fig. 2.7B).  
 
Discussion 
Identifying orphan biosynthetic gene clusters through genome mining has proven 
to be a successful approach toward the discovery of novel small molecule secondary 
metabolites.5, 33-37  The moderately thermophilic actinomycete, T. fusca, contains one 
gene cluster belonging to the NRP family of natural products.  The cluster contains the 
hallmarks of siderophore producing enzymes, with biosynthetic pathways that yield the 
iron chelating 2,3-dihydroxybenzoyl and hydroxamate ligands.  Although the enzymatic 
components of the fuscachelin cluster have homologs in other siderophore NRP 
Fig. 2.7    (A)  The fuscachelin termination module FscI (148 kDa) was overexpressed in E. 
coli and purified to homogeneity, as shown by SDS-PAGE analysis.  (B)  The pyrophosphate 
exchange assay for A-domain activity was performed with FscI using all 20 proteinogenic 
amino acids, L-ornithine and L-HOOrn.  FscI was shown to be most active with L-HOOrn, 
connecting the fsc gene cluster with fuscachelin biosynthesis. 
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synthetases, the combination and organization of the fsc genes are unique.  Siderophore 
natural products most often bind to extracellular ferric ions through the formation of a 
hexacoordinate, octahedral chelation complex.38-40  The T. fusca siderophore is able to 
achieve this through the production of a heterodimeric nonribosomal peptide with two 
terminal catechols and an internal hydroxamate.  The biosynthetic pathway for this 
siderophore, termed fuscachelin A, is unusual and prediction of the structure of the 
natural product would not be possible based on analysis of the genomic sequence 
alone.  Namely, unambiguous assignment of the adenylation domains, prediction of 
macrocyclization and the unusual nonlinear biosynthetic pathway were unexpected. 
We initially characterized a siderophore natural product (fuscachelin B) from T. 
fusca as a linear octapeptide N-capped with two 2,3-dihydroxybenzoic acids and an 
internal N-α-N-δ-linked N−δ-hydroxyornithine.  The structure was determined with 
detailed NMR and mass spectrometric characterization of the isolated product.  A 
second fraction in the purification (fuscachelin C) exhibited nearly identical 
characteristics to fuscachelin B, with the notable exception of a 1 dalton mass difference, 
corresponding to a change of an oxygen atom to an NH.  This change was localized by 
NMR and mass spectral fragmentation data to the L-HOOrn subunit, specifically as an α-
carboxamide group.  A third product was isolated from T. fusca that displayed similar 
properties to fuscachelin B and C, and slowly decomposed over time, or rapidly with 
alkali treatment, to fuscachelin B.   This product (fuscachelin A) was characterized as a 
macrolactone, and based on the predicted biosynthetic pathway is most likely the initial 
natural product produced by the T. fusca NRP synthetase machinery.  We believe 
fuscachelins B and C are degradation products of fuscachelin A, resulting from 
nucleophilic opening of the 10-membered macrolactone: hydrolysis to form fuscachelin B 
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and aminolysis (the growth media contains 24 mM ammonium sulfate) to form 
fuscachelin C.   
The predicted biosynthetic pathway (Fig. 2.8) for fuscachelin A contains well-
characterized genes for the biosynthesis of a peptidic siderophore, although there are 
several unusual features.  The condensation domain of FscI couples both DHB-Arg-Gly-
Gly and DHB-Arg-Gly-Gly-Ser to the δ-and α-nitrogens of L-HOOrn bound to the T 
domain of FscI.  The two coupling partners originate from the carrier domains of FscG 
and FscH. The second coupling (as diagrammed in Fig. 2.8) between FscI and FscG 
involves the skipping of module FscH, an example of non-linear, type C NRPS 
assembly, observed in a limited number of NRP pathways.41  The coupling of two T-
domain bound acyl intermediates to L-HOOrn and the predicted module skipping is 
reminiscent of the chemistry of the NRP synthetase CchH in coelichelin biosynthesis 
Fig. 2.8    The proposed biosynthetic pathway to fuscachelin A.  The mature fuscachelin 
decamer is not transferred to the TE of FscI (1) until FscG acts twice; only then can the 
macrolactonization step (2) occur. 
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(see Fig. 1.10, chapter 1).42  Following the tandem couplings to the L-HOOrn core, the 
thioesterase domain of FscI performs a macrocyclization to form the 10-membered 
depsipeptide ring of fuscachelin A.  The FscI TE domain shows significant homology to 
the thioesterase DhbF of bacillibactin biosynthesis.43  DhbF catalyzes a related reaction, 
the cyclotrimerization of DHB-Gly-Thr to form the 12-membered macrolactone 
siderophore.  To confirm the activity of the gene cluster, fscI was cloned from T. fusca 
and overexpressed in E. coli.  The adenylation domain of the purified protein was 
biochemically demonstrated to prefer the nonproteinogenic amino acid L-N−δ-
hydroxyornithine.  This result both establishes the role and position of the NRP 
synthetase FscI in the pathway and demonstrates that the flavin monooxygenase (FscE) 
acts on the free amino acid L-ornithine and not the mature peptide.  
Here, we present the structure elucidation of a novel siderophore from the 
thermophilic actinomycete T. fusca.  The natural product was discovered using a 
genome-mining approach.  Fuscachelin A is the first secondary metabolite isolated from 
this bacterium and the described natural product gene cluster is one of only a few from 
any thermophilic species.  The proposed biosynthetic pathway contains unusual aspects 
that demonstrate the flexibility of NRP assembly-line chemistry to construct biologically 
active peptides and the structure of fuscachelin A represents a new molecular 
architecture for the chelation of iron.  
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Materials and Methods 
Purification of Fuscachelins A, B and C.  
T. fusca spores (ATCC 2773) were used to inoculate 5 mL liquid cultures grown in LB 
broth at 55 ºC and 150 rpm.  After 48 h, the cells were thoroughly exchanged into 5 mL 
of iron-deficient Hägerdal media by repeated centrifugation and used to inoculate 1 L 
liquid cultures, also in iron-deficient Hägerdal media.29  1 L cultures were grown for 7 
days at 55 ºC and 150 rpm. Cells were pelleted at 10,000 rpm and 4 ºC for 30 min using 
a Beckman Coulter J2-HS centrifuge.  Cell pellets were collected and extracted 5X with 
30 mL portions of methanol.  The methanol extracts were concentrated in vacuo to a 
small volume (~5 mL) and siderophore activity was confirmed using the chrome azurol S 
(CAS) assay of Schwyn and Neilands.30  CAS positive extracts were concentrated to 
dryness and subjected to two rounds of preparative HPLC using a Vydac 218TP1022 
Protein and Peptide C18 column (250 x 22 mm, 10 mm) on a Shimadzu LC-6AD liquid 
chromatography system equipped with a Shimadzu SPD-10A UV-Vis detector.  A 
detection wavelength of 320 nm was chosen to monitor elution of the 2,3-
dihydroxybenzoyl moiety.  A linear gradient of 2-50% methanol in 0.1% TFA/water was 
run over 30 min at 10 mL min-1.  CAS positive fractions were collected between 23-28 
min and lyophilized.  The lyophilized material was dissolved in 5 mL of 23% 
methanol/water.  1 mL portions were injected onto the column and purified using a linear 
gradient of 23-33% methanol in water/0.1% TFA over 60 min at 8 mL min-1.  Three CAS 
positive fractions were collected at 17.1 min, 18.6 min and 22.8 min. Lyophilization of the 
CAS positive fractions afforded 2.0 mg, 3.0 mg and 2.3 mg of fuscachelins C, B and A, 
respectively, as white solids.  The fourth CAS positive fraction (eluting at 24.8 min) was 
free 2,3-dihydroxybenzoic acid as judged by 1H NMR.  Samples for 15N NMR analysis 
 65 
were prepared in an identical fashion with the exception that (15NH4)2SO4 (99% 15N, 
Cambridge Isotope Laboratories, Inc.) was included in the Hägerdal media as the sole 
nitrogen source.   
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HPLC (320 nm and 220 nm) of T. fusca extracts obtained from iron depleted and iron 
supplemented Hägerdal medium.  In the presence of iron supplemented growth medium, 
production of the fuscachelins is suppressed. 
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NMR Structure Elucidation of the Fuscachelins.    
All NMR spectra were acquired using a D2O susceptibility matched 5 mm Shigemi© 
advanced NMR microtube. NMR solvents were purchased from Cambridge Isotope 
Laboratories, Inc. 1H, 13C, 15N and 1H-13C correlation spectra were acquired on a Varian 
INOVA 500 MHz (1H) NMR spectrometer using VNMR 6.1C software.  Spectra were 
processed using MestReC version 4.9.9.8 software.  Spectra acquired in D2O were 
referenced to the residual HOD peak.  In cases where an H2O/D2O (4:1) solvent mixture 
was used to observe backbone amide protons and exchangeable side chain protons, the 
intense solvent peak was suppressed using the PRESAT and solvent suppression 
parameters in the VNMR 6.1C software. 1H, TOCSY (512 increments, 64 transients, 80 
ms mixing time), gCOSY (512 increments, 48 transients), gHSQC (512 increments, 32 
transients) and gHMBC (512 increments, 64 transients) spectra were acquired using a 
Varian 500 ID/PFG 50-202 MHz inverse probe.  13C and 15N spectra were acquired using 
a Varian 500 SW/PFG 50-202 MHz broadband probe.  13C spectra were referenced to 
CD3OD, which was used as an internal standard.  15N spectra were externally referenced 
to 2.9M 15NH4Cl/1 M DCl in D2O (Cambridge Isotope Laboratories, Inc.).  1H-15N 
correlation spectra (gHSQC - 256 increments, 4 transients and gHMBC - 128 
increments, 16 transients) were acquired on a Varian VNMRS 600 MHz (1H) NMR 
spectrometer equipped with a 5 mm HCN AutoX inverse probe.   
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500 MHz 1H NMR (D2O) spectrum of fuscachelin B. 
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500 MHz 1H NMR spectrum of fuscachelin B (between δ 6.50 – 9.00) in 4:1 H2O/D2O.  
Integration of the backbone amide and aromatic signals clearly indicate the relative 
number of amino acid residues and dihydroxybenzoic acid moieties in the fuscachelin 
peptide (2×Arg, 4×Gly, 1×Ser, 1×HOOrn, 2×DHB). 
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500 MHz 1H NMR spectrum of fuscachelin B (between δ 3.90 and 5.10). Integrals of alpha 
protons reflect the ratio of amino acids in the fuscachelin peptide (1×Ser, 2×Arg, 1×HOOrn, 
4×Gly). 
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500 MHz gCOSY (D2O) spectrum of fuscachelin B.  Vicinal couplings are highlighted. 
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500 MHz TOCSY spectrum of fuscachelin B in 4:1 H2O/D2O.  The characteristic signals of the 
individual amino acid spin systems are highlighted. 
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125 MHz proton-decoupled 13C NMR (D2O) spectrum of fuscachelin B.   
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500 MHz (1H) 1H-13C gHSQC (D2O) spectrum of fuscachelin B.  The DHB aromatic signals are 
given in the inset. 
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500 MHz (1H) 1H-13C gHMBC (D2O) spectrum of fuscachelin B.  Important aromatic and side 
chain correlations are highlighted. 
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500 MHz (1H) 1H-13C gHMBC (D2O) spectrum of fuscachelin B (δ 3.00 - 5.50 in f1, δ 150 -
190 in f2) highlighting key alpha 1H - carbonyl correlations. 
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Overlay of the 1H NMR spectra of fuscachelins B and C.  The subtle differences in the HOOrn 
signals are highlighted. 
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Overlay of the 125 MHz proton-decoupled 13C NMR spectra of fuscachelins B and C.  A 
difference in the chemical shift of the HOOrn alpha carbonyl (position 32, fuscachelin B 
carboxyl; fuscachelin C carboxamide) signal is evident. 
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Fig. S12    Overlay of the 50 MHz proton-decoupled 15N NMR spectra of fuscachelins B and 
C.  The L-HOOrn carboxamide nitrogen (denoted N32) is highlighted in the fuscachelin C 
spectrum. 
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Comparison of the 600 MHz (1H) 1H-15N gHSQC (D2O) spectra of fuscachelins B and C.  The 
fuscachelin C carboxamide N-H signals are well defined.  The difference in the chemical shifts 
of the HOOrn amide signals (position 33, 1H and 15N) as a result of the differing functionalities 
at position 32 are evident. 
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600 MHz (1H) 1H-15N gHMBC (D2O) spectrum of fuscachelin B highlighting key side chain and 
amide correlations. 
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Overlay of the 500 MHz 1H NMR (D2O) spectra of fuscachelin B, the initial isolate of 
fuscachelin A and fuscachelin A nine days after isolation.  Degradation of A to B is clear given 
the well-defined change in chemical shifts of the Ser and HOOrn signals.   
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500 MHz gCOSY (D2O) spectrum of the initial isolate of fuscachelin A (δ 1.50 - 5.00) 
highlighting the Ser and HOOrn coupling. 
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Mass Spectrometric Analysis of the Fuscachelins.   
High resolution ESI+ single mass analysis was performed on an Agilent LC/MSD TOF 
mass spectrometer equipped with Agilent Technologies 1100 Series cap-LC pumps.  
MS/MS experiments were performed on an Applied Biosystems/MDS SCIEX 4800 
MALDI TOF/TOF mass spectrometer.  A ferric fuscachelin B complex was prepared by 
mixing purified fuscachelin B with 1% FeCl3 in a 1:1 siderophore:Fe ratio.44  The solution 
was mixed at room temperature for 2 h and lyophilized.  The dried sample was subjected 
to ESI+ analysis using a Micromass LCT TOF mass spectrometer. 
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ESI+ TOF MS of fuscachelin B.  (predicted m/z [M+H]+: 1048.4448, C42H62N15O17+; observed 
m/z [M+H]+: 1048.4448, C42H62N15O17+) 
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ESI+ TOF MS of fuscachelin C.  (predicted m/z [M+H]+: 1047.4608, C42H63N16O16+; observed 
m/z [M+H]+: 1047.4614, C42H63N16O16+) 
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ESI+ TOF MS of fuscachelin A (predicted m/z [M+H]+: 1030.4342, C42H60N15O16+; observed 
m/z [M+H]+: 1030.4344, C42H60N15O16+) with degradation product fuscachelin B.   
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MALDI TOF MS of ferric fuscachelin B.  (predicted m/z [M-2H+Fe3+]+: 1101.3557, 
C42H59N15O17Fe+; observed m/z [M-2H+Fe3+]+: 1101.3600, C42H59N15O17Fe+) 
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MALDI TOF TOF spectrum of fuscachelin B and fragmentation pattern. 
 
 90 
 
 
 
 
MALDI TOF TOF spectrum of fuscachelin C.  Fragments containing HOOrn show a marked 
decrease of 1 Da compared to analogous fragments obtained from fuscachelin B. 
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Determination of Amino Acid Chirality Using Marfey’s Method.   
500 µg of fuscachelin B was dissolved in 400 µL of 6 M HCl and heated at 110 ºC for 24 
h.  The mixture was lyophilized and the residue dissolved in 10 µL of water, 20 µL of 1 M 
NaHCO3 and 170 µL of 1% Marfey’s Reagent (N-α-(2,4-dinitro-5-fluorophenyl)-L-
alaninamide, Sigma-Aldrich) acetone solution and heated at  37 ºC for 1 h.  The reaction 
was quenched with 20 µL of 1 M HCl and the mixture lyophilized.  The dried products 
were dissolved in 1:1 water:acetonitrile 0.1% TFA solution to a final volume of 400 µL 
and analyzed on a Vydac 218TP54 Protein and Peptide C18 HPLC column (250 x 4.6 
mm, 5 mm) on a Shimadzu LC-6AD liquid chromatography system equipped with a 
Shimadzu SPD-10A UV-Vis detector.  The separation was performed using a linear 
gradient of 0 – 52.5% buffer B (10 mM ammonium formate, 1% methanol, 60% 
acetonitirile, pH 5.2) in buffer A (10 mM ammonium formate, 1% methanol, 5% 
acetonitrile, pH 5.2) over 45 min using detection wavelengths of 340 and 220 nm, an 
injection volume of 5 µL and a volume flow rate of 1 mL min-1.31  Stereochemical 
assignments were made via comparison to the retention times of Marfey’s derivatives 
prepared from authentic amino acid standards of D/L–arginine, D/L–serine, D/L–
ornithine, and glycine (Sigma-Aldrich).  In addition, the peak for L-N-δ-hydroxyornithine 
was identified using the Marfey’s derivative of a synthetic standard of L-N-δ-
hydroxyornithine that was chemically synthesized using an established protocol.32 
Marfey’s derivatives of HPLC amino acid standards were prepared by mixing 50 µL of 50 
mM (aq) amino acid, 100 µL of 1% Marfey’s reagent/acetone solution and 20 µL of 1 M 
NaHCO3, heating at 37 ºC for 1 h, lyophilizing and dissolving in 1:1 water:acetonitirle 
0.1% TFA solution to a final volume of 400 µL.  Separation of the standard mixture was 
optimized to the conditions outlined above. 
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Fuscachelins A and B - HPLC Peak Shift Analysis.   
HPLC samples were run on a Vydac 218TP54 Protein and Peptide C18 HPLC column 
(250 x 4.6 mm, 5 mm) at a column temperature of 30 ºC using a linear gradient of 0.5 – 
20% B (acetonitrile/ 0.1% TFA) in A (water/ 0.1% TFA) over 27 min at 1 mL min-1 
following a 3 min wash with 0.5% B in A.  HPLC traces were acquired using 
spectrophotometric detection.  20 µL of 5 mM samples of fuscachelins A and B (in water) 
were run as standards.  Then, a 50 µL sample of 5 mM fuscachelin A in 1 M NaOH was 
agitated at room temperature for 3 h.  PyBOP mediated lactonization was run in N,N-
dimethylformamide.  4 µL of fuscachelin B (0.4 µmol, from a 0.1 M stock solution) were 
added in 1 µL portions every two hours over the course of 8 hours to a mixture of 
PyBOP (1.6 µmol, 16 µL from a freshly prepared 0.1 M solution in DMF) and DMAP 
(12.0 µmol, 120 µL from a freshly prepared 0.1 M solution in DMF) in a total volume of 
200 µL of DMF.  The reaction was allowed to proceed over night at 37 ºC.  Analytical 
HPLC samples were prepared by adding 5 µL of the crude reaction mixture to 15 µL of 
HPLC solvent A and were analyzed using the gradient conditions outlined above.   
 
Cloning, Expression and Purification of FscI.   
The gene for fscI was amplified using PCR from T.fusca genomic DNA with the following 
primers:  5´ GCG GAA TTC ACC ACC GCA GCC GCG GGT (EcoRI), 5´ GCG AAG CTT 
CTA GCT GTG TCC GGA TCG (HindIII).  The PCR products were purified through 
agarose gel electrophoresis and gel extraction (Qiagen) and cleaved with the EcoRI and 
HindIII restriction endonucleases.  The fscI gene was then ligated into the plasmid 
pET30a.  The plasmid was transformed into E. coli BL21(DE3) cells for gene expression.  
Cultures (1 L) were grown to O.D.600 = 0.5-0.7 at 37 ºC, at which point the shaker was 
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cooled to 18 ºC and overexpression was initiated by addition of 50 mM IPTG.  Cultures 
were continued for 18 h and were harvested by centrifugation, followed by resuspension 
in 500 mM NaCl, 20 mM Tris-HCl (pH 7.5) and lysed by passage through a French 
Press Cell at 1000 psi.  Lysate was centrifuged at 10,000 rpm for 20 min.  The 
supernatant was incubated for 1 h with 1 mL metal-affinity resin (Talon resin, Clontech).  
Resin was washed with 4X 10 mL 500 mM NaCl, 20 mM Tris-HCl (pH 7.5),  Protein was 
eluted with 2X 10 mL 500 mM NaCl, 20 mM Tris-HCl (pH 7.5), 250 mM imidazole.  
Protein was dialyzed against 100 mM NaCl, 20 mM Tris-HCl (pH 7.5), 1 mM β-
mercaptoethanol, 10% (v/v) glycerol, concentrated to 17 mM and flash frozen.   
 
Pyrophosphate exchange assay.   
Amino acid dependent ATP-sodium pyrophosphate assays were performed as follows:  
A 100 mL reaction contained 75 mM Tris-HCl (pH 8.0), 10 mM MgCl2, 5 mM DTT, 5 mM 
ATP, 1 mM Na432P2O7, 100 mg mL-1 BSA, 1 mM amino acid, 2 mM FscI.  Reactions 
were initiated by addition of enzyme, and incubated at 30 ºC for 0.5 h.  The reaction was 
quenched by addition of 500 mL 3.5% charcoal, 1.6% perchloric acid, 200 mM Na4P2O7.  
The charcoal was centrifuged and re-suspended twice with 500 mL 1.6% perchloric acid, 
200 mM Na4P2O7.  After washing, the charcoal was mixed with 3 mL of scintillation fluid, 
and read by a Beckman Coulter LS 6500 scintillation counter.  All reactions were 
performed in triplicate. 
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Chapter 3 
 
Total Synthesis of Fuscachelins A & B and 
Preparation of Fuscachelin-Ga(III) Complexes 
 99 
Introduction 
 The impetus to undertake a total synthesis of a natural product often stems from 
the chemist’s desire to study further or understand better the structural, chemical and 
biological properties of a molecule.  Additionally, nature usually provides only very small 
quantities of the molecules of interest, necessitating the development of an alternate 
source of the compounds.  When considering newly discovered molecules, chemical 
synthesis can provide a direct and rigorous method of structural proof as well.  Our 
recent discovery of the fuscachelins, nonribosomal peptide siderophores from the 
thermophilic actinomycete Thermobifida fusca, serves as a stepping-off point to a more 
comprehensive examination of the fuscachelin nonribosomal peptide biosynthetic 
enzymes.1  To this end, it became obvious early on that the tools of chemical synthesis 
would be necessary to study and exploit the chemistry of this system.  A flexible 
synthetic route to the siderophore natural products would afford additional quantities of 
the molecules, establish a platform from which custom-designed inhibitors or substrates 
of biosynthetic enzymes could be synthesized and would also implicitly provide an 
additional means of structure elucidation.  Several of these points will be discussed 
further in chapter 4.  Below, we present the total synthesis of the fuscachelins.   
Retrosynthetic Analysis of Fuscachelin A 
 The fuscachelins are decameric peptide siderophores with a scaffold that 
consists of eight peptide bonds, one hydroxamic acid linkage and one depsipeptide bond 
that serves to form the 10-membered lactone of fuscachelin A (1).  In our structure 
elucidation studies, it became clear that the lactone was very susceptible to hydrolytic 
degradation.  For this reason, macrolactone formation was reserved for the  
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last step of the synthesis, which conveniently afforded fuscachelin B (2) as the first 
retrosynthon (Scheme 1).  Fuscachelin B can be viewed as a “core” (L,L)-N-δ-serinyl-(N-
δ-hydroxy)ornithine (Ser-HOOrn, 4) dipeptide that is flanked on its N-termini by a (D)-
2,3-dihydroxybenzoyl-argininyl-glycinyl-glycine (DHB-Arg-Gly-Gly, 3) tetramer.  Re-
trosynthetic cleavage of the two amide bonds connecting the core peptide to the flanking 
tetramer gives synthons 3 and 4.  These were viewed as readily accessible synthetic 
intermediates that would be amenable to the convergent assembly of the natural 
Scheme 1.    Retrosynthetic analysis of Fuscachelin A 
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product’s decameric backbone.  To bind iron, the fuscachelins employ two 2,3-
dihyroxybenzoyl moieties and one hydroxamic acid, providing six oxygen ligands for 
chelating a ferric iron center.  These groups are known to be extraordinarily sensitive to 
trace amounts of metal and make normal methods of purification (including purification 
on silica gel) very difficult, if not impossible.  Thus, it was deemed necessary to protect 
this functionality until a very late stage in the synthesis.  The benzyl protecting group 
was chosen as it is stabile under the conditions experienced during normal Boc and 
Fmoc peptide deprotection strategies.  Further, the benzyl group is, in general, easily 
removed under mild hydrogenolytic conditions.  Taken together, these considerations led 
directly to the commercially available arginine, diglycine, serine and glutamic acid 
building blocks and the readily accessible 2,3-(dibenzyloxy)benzoic acid as our final 
retrosynthons. 
Synthesis of the 2,3-DHB-Arg-Gly-Gly Core-Flanking Tetramer 
  
Of the three building blocks required to construct the 2,3-DHB-Arg-Gly-Gly 
tetramer, two, (D)-N-α-Fmoc-Nη-Pmc-arginine and glycinylglycine benzyl ester, are 
commercially available.  The third, 2,3-(dibenzyloxy)benzoic acid must be prepared.  
This can be achieved using a well established, two step sequence starting from 2,3-
dihydroxybenzoic acid (DHB).2  Global benzyl protection of the DHB starting material 
Scheme 2.  Preparation of 2,3-(dibenzyloxy)benzoic acid 
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followed by saponification of the benzyl ester under aqueous, basic conditions gives the 
desired building block.  The resultant free acid is then available to participate in a 
peptide coupling reaction while the catechol oxygens remain protected. (5, Scheme 2).  
The route to the fuscachelin core-flanking tetramer involved two, straightforward 
peptide bond forming reactions.  In the first step, the amide linkage between 
glycinylglycine benzyl ester and (D)-N-α-Fmoc-Nη-Pmc-arginine is formed in a 
DCC/HOBt mediated peptide coupling reaction.  This is followed by cleavage of the N-α-
Fmoc protecting group on the arginine residue using piperidine, which affords 6.  A 
second DCC/HOBt coupling reaction is then performed to link 5 and 6, followed by 
hydrolysis of the C-terminal benzyl ester to provide 3 (Scheme 3).   
 
 
 
 
 
 
 
Preparation of the Fuscachelin “core” Dipeptide, Ser-HOOrn 
 The fuscachelin core contains the important hydroxamate functionality that 
results from linkage of the Ser-C-α acid and the HOOrn-N-δ sidechain hydroxylamine.  
Scheme 3.    Synthesis of core-flanking tetramer DHB-Arg-Gly-Gly. 
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As was discussed in chapter 1, there are numerous ways to construct hydroxamic acids 
and several of these approaches were explored in the synthesis of the structurally novel 
fuscachelin Ser-HOOrn core (Fig. 3.1).   
 
Both the norvaline N-substition and the ornithine N-δ-acylation pathways called for a 
norvaline-based, C-δ electrophile that would allow for substitution with a nitrogenous 
nucleophile.  Several of these electrophilic substrates were prepared from a 5-
hydroxynorvaline (7) precursor (Scheme 4).  This compound was generated via the 
NaBH4 mediated reduction of the sidechain acid of (L)-N-α-Boc-glutamic acid benzyl 
ester.3  Treatment of alcohol 7 with carbontetrabromide in the presence of 
triphenylphosphine yields primary bromide 9.3-5  This is easily converted to the iodide (8) 
upon treatment with NaI in refluxing acetone.  In addition, tosylate 10 can be prepared 
by treating 7 with p-toluenesulfonyl chloride in pyridine.6   
Initially, we planned on performing N-δ-acylation as the final step in the 
construction of the core hydroxamate.  Thus, we attempted to make the two, O-protected 
hydroxyornithine derivates shown in Scheme 5.  One scenario employed the 
methodology of Phanstiel to generate the O-benzoyl protected hydroxyornithine  
Fig. 3.1    Options for assembling the Ser-HOOrn, 
core-dipeptide hydroxamate. 
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derivative 12 from 11.7, 8  A second scheme utilized iodide 8 and O-benzylhydroxylamine 
to form 13.  In both cases, the undesired cyclization of the side chain amine of ornithine 
upon the α-carboxyl benzyl ester protecting group resulted in the formation of 14 
instead.  It was clear from these results that the benzyl ester functionality would not 
tolerate the presence of a side chain nucleophile.  As we desired to retain the benzyl 
ester as part of our protecting group scheme, these approaches were quickly 
abandoned. 
  
 
 
 
 
 
Scheme 4.    Synthesis of norvaline, C-δ electrophiles. 
Scheme 5.    Attempts to prepare hydroxyornithine via N-oxidation. 
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A different approach to the hydroxamic acid was then adopted, in which the O-
benzyl protected hydroxamate 15 is made in one step.  In a second step, the protected 
hydroxamate is N-alkylated with a C-δ electrophilic norvaline derivative (8-10).  The 
general approach is outlined in Fig. 3.2.  The caveat to this approach is that 
hydroxamate O-alkylation competes with N-alkylation, providing undersired side product 
17 in addition to N-alkylated 16. 
 
 
 
 
 
 
The extent of this competeing reaction has been shown to be highly dependent on the 
electrophile.5, 6, 9  For this reason, it was important to test the regioselectivity of norvaline 
derivatives 8-10 in this reaction.  Treatment of O-benzylhydroxamate 15 with 
electrophiles 8-10 under basic conditions gave a wide range of regioselectivities, but it 
was only bromide 9 that provided a ratio of 16:17 greater than 1 (Scheme 6). 
Having settled on 9 as the ornithine precursor, the convergent assembly of the 
hydroxamate core dipeptide depicted in Scheme 7 was settled upon.  (L)-N-Boc-O- 
Fig. 3.2    Synthetic plan for assembly of the Ser-HOOrn core-dipeptide via N-
substitution of a norvaline electrophile. 
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benzylserine-O-benzylhydroxamate 15 is prepared in one step via treatment of (L)-N-
Boc-O-benzylserine with O-benzylhydroxylamine under DCC peptide coupling 
conditions.  Bromide 9 was prepared as depicted in Scheme 4 and the N- and O-
alkylated products 16 and 17 were prepared as shown in Scheme 6.  Separation of 16 
from 17 on silica and subsequent treatment of 16 with neat TFA gave core dipeptide 4.   
 
Preparation of the Fuscachelin Peptide 
With the key intermediates 3 and 4 in hand, we were now poised to perform the 
convergent assembly of the complete fuscachelin peptide.  In a double peptide coupling 
Scheme 6.    Regioselectivity of N-alkylation of 15 using electrophiles 8-10. 
Scheme 7.    Convergent assembly of the Ser-HOOrn core-dipeptide. 
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reaction, DCC and HOBt in THF gave fully protected fuscachelin B (18) in 49% yield.  
Treatment of this product with a solution of 95:5:0.1 TFA:water:thioanisole cleanly 
removed the Pmc groups from the guanidium group of arginine to afford benzylated 
peptide 19 (Scheme 8) .10-12   
 
 
 
 
 
 
 
 
 
 
 
 
Having prepared 19, we simply needed to perform a global deprotection of the 
remaining benzyl ethers and ester.  This seemingly straightforward transformation turned 
out to be more challenging than initially anticipated.  The intermediate 19 was found to 
Scheme 8.    Convergent synthesis of the fuscachelin decamer. 
. 
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be insoluble in almost all common organic solvents, with sparing solubility in methanol.  
In addition, standard hydrogenolysis catalysts were completely ineffective under ambient 
pressure.  Increased hydrogen pressures were screened using 10% Pd/C, but this also 
failed to afford the desired product.  Performing the reaction in glacial acetic acid or a 
mixture of 3:1 glacial acetic acid and methanol in the presence of carbon supported Pd, 
Pt and Rh catalysts failed as well.  Finally, the more reactive catalyst, Pd black, was 
tested in 3:1 glacial acetic acid and methanol.  Using catalytic quantities HClO4, this 
method provided a trace amount of fuscachelin B.13, 14  Unfortunately, the bulk of the 
material was converted to completely insoluble degradation products.  By simply omitting 
the catalytic perchloric acid, 19 was converted to 2 in reasonable yield (Scheme 9).   
 
 Several macrolactonization conditions were screened in an effort to elaborate 
fuscachelin B to fuscachelin A.  Combinations of the coupling reagents PyBOP/DMAP, 
EDC/DMAP and DCC/HOBt, in addition to Yamaguchi lactonization conditions using  
Scheme 9.    Global deprotection of benzyl-protected fuscachelin B. 
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Yonemitzu’s modification, were attempted.15  Reaction progress was monitored using 
HPLC.  The DCC and Yamaguchi procedures failed to produce any lactone.  PyBOP 
and DMAP provided low yield of the lactone, but left most of the starting material 
unconverted.  A combination of EDC and DMAP proved to be the most successful route 
to 1, providing fuscachelin A in 75% yield (Scheme 10).   
Gallium Complexes of the Fuscachelin Peptides 
In nature, siderophores are produced by microorganisms to selectively bind 
iron(III).  In the laboratory, it is often undesirable to work with ferric-siderophore 
complexes because the paramagnetism of iron makes NMR experiments impossible to 
perform.  Additionally, the possibility of ligand decomposition via the iron-catalyzed 
formation of reactive oxygen species is a concern.  Frequently, gallium(III)-siderophore 
complexes are prepared in lieu of iron complexes.  They have proven to be easy to 
synthesize and purify, are amenable to NMR and crystalographic analysis, tend to be 
stable and have even shown promise as antimicrobial agents in several studies.16-20  For 
these reasons, we thought it important to establish a route for the preparation of gallium 
complexes of the fuscachelins.  This can be achieved by simply treating 1 or 2 with an 
Scheme 10.    Macrolactonization of 2 to give Fuscachelin A. 
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excess of aqueous GaBr3.  HPLC purification of the reaction mixture affords the gallic 
complexes, 20 and 21, of 1 and 2 in reasonable yield (Scheme 11).   
 
 
 
 
 
 
 
 
Scheme 11.    Synthesis of fuscachelin-Ga(III) complexes. 
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Conclusion 
 Here, we have presented a synthetic route to fuscachelins A and B.  Completion 
of the total synthesis provided concrete evidence that the structures that were previously 
determined using spectroscopic and chemical degradation methods were correct.  The 
convergent nature of the synthesis established 3 and 4, the DHB-Arg-Gly-Gly “core 
flanking” peptide and the Ser-HOOrn “core”, respectively, as key intermediates. 
Additionally, these compounds were designed to serve as sources of readly available 
biochemical tools that could prove useful in studying the enzymes involved in 
fuscachelin biosynthesis.  This topic will be explored in chapter 4.  The synthetic 
preparation to these two intermediates are straightforward and provide useful quantities 
of the material.  The bottleneck of the synthesis proved to be the global deprotection of 
the benzyl protecting groups, which played the important role of masking the sensitive 
iron-chelating functionality and reactive loci in the core peptide.  Fortunately, the 
macrolactone of fuscachelin A is readily accessible once fuscachelin B is in hand.  
Having established a synthetic route to these molecules should prove useful in future 
studies of the fuscachelins with regard to both their biosynthesis and utilization by T. 
fusca.   
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Materials and Methods 
General Experimental Methods.  Unless stated otherwise, reactions were performed 
under an atmosphere of dry nitrogen in flame-dried glassware and stirred with teflon 
coated magnetic stir bars.  Dry acetone and methanol were prepared via distillation over 
CaSO4.  All other organic solvents were obtained from a solvent purification system or 
were purchased anhydrous from commercial suppliers.  Flash chromatography was 
performed with 32-63 µm, 230-400 mesh active silica gel.  Thin layer chromatography 
(TLC) was performed on Silica Gel 60 F254, 250 µm, glass-backed normal phase plates.  
TLC plates were visualized under short wave UV illumination and/or were stained by 
dipping in iodine coated silica or 1% w/v ninhydrin in 3% v/v acetic acid/ethanol and 
subsequently heated with a heat gun.  NMR spectra were acquired on either a Varian 
Unity 400 MHz or INOVA 500 MHz NMR spectrometer and were analyzed using 
MestReNova v5.3.1-4825 NMR processing software.  NMR solvents were purchased 
from Cambridge Isotope Laboratories.  Spectra were referenced to internal 
tetramethylsilane standard or residual protio-solvent.  All NMR chemical shifts are 
reported in δ (ppm downfield from tetramethylsilane) and all coupling constants (J) are 
reported in Hertz (Hz).  1H NMR peak multiplicities are reported as s (singlet), d 
(doublet), t (triplet), q (quartet), dd (doublet of doublets), b (broad), m (multiplet). The 
following abbreviations are used:  Boc: t-butoxycarbonyl;  DCC: dicyclohexyl-
carbodiimide;  DCM: dichloromethane;  DHB: dihydroxybenzoyl;  DI H2O: deionized 
water;  DIPEA: diisopropylethylamine;  DMAP: 4-(dimethylamino)pyridine;  DMF: N,N-
dimethylformamide;  EDC:  N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide;  Et2O: 
diethyl ether;  EtOAc: ethyl acetate;  Fmoc:  9-fluorenylmethoxycarbonyl;  HOBt: 1-
hydroxybenzotriazole;   IPA: isopropyl alcohol;  MeOH: methanol;  TFA: trifluoroacetic  
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2,3-bis(dibenzyloxy)benzoic acid (5).  2,3-dihydroxybenzoic acid (0.62 g, 4.0 mmol) 
and K2CO3 (10.0 g, 72.4 mmol) were taken up in 80 mL of acetone.  Benzyl bromide 
(2.86 mL, 24.2 mmol) was added to the stirring solution and the mixture was refluxed at 
85 ºC for 24 h under the exclusion of light.  The solution was concentrated in vacuo to a 
yellow oil.  The oil was then dissolved in 240 mL of MeOH to which 60 mL of 5 M NaOH 
was added.  The reaction was refluxed at 100 ºC for 3 h.  MeOH was then removed in 
vacuo.  The aqueous concentrate was diluted with 20 mL DI H2O and washed twice with 
hexanes.  The aqueous layer was then acidified to pH 2 with 3 N HCl and the resulting 
white precipitate was collected and dried under high vacuum (1.21 g, 90%).  Rf = 0.8 
(20% IPA/CHCl3).  1H NMR (500 MHz, CDCl3) δ 7.74 (dd, J = 7.9, 1.6 Hz, 1H), 7.50 – 
7.32 (m, 10H), 7.26 (dd, J = 8.1, 1.7, 1H), 7.19 (t, J = 8.0 Hz, 1H), 5.27 (s, 2H), 5.20 (s, 
2H). 13C NMR (125 MHz, CDCl3) δ 165.1, 151.3, 147.1, 135.8, 134.6, 129.3, 129.3, 
128.9, 128.8, 128.6, 127.8, 125.1, 124.5, 119.0, 77.2, 71.6.  ESI- MS calc for C21H17O4 
[M-H]- 333.1, found 333.0. 
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(D)-(N-η-Pmc-argininyl)glycinylglycine benzyl ester (6).  Glycinylglycine benzyl ester 
p-toluenesulfonate (2.38 g, 6.0 mmol) was taken up in 20 mL of THF and then DIPEA 
(3.14 mL, 18 mmol) was added to the slurry and the solid was allowed to disolve at room 
temperature.  Meanwhile, (D)-N-α-Fmoc-N-η-Pmc-arginine (2.00 g, 3.0 mmol) and HOBt 
(0.489 g, 3.6 mmol) were taken up in 40 mL THF and cooled to 0 ºC.  DCC (0.747 g, 3.6 
mmol) was then added to the mixture and the OBt ester was allowed to form for 10 min.  
The glycinylglycine benzyl ester p-toluenesulfonate/DIPEA mixture was then added 
dropwise and the reaction was allowed to slowly warm to room temperature over 2 h.  
Solid was removed via filtration through a plug of celite and a silica column was run 
(20% IPA/CHCl3) to afford the tripeptide product as a white solid (2.71 g, theoretical 
yield: 2.62 g).  Rf = 0.7 (20%IPA/CHCl3).  1H NMR (400 MHz, CDCl3) δ 7.80 (t, J = 5.3 
Hz, 1H), 7.69 (d, J = 7.5 Hz, 2H), 7.54 (t, J = 5.9 Hz, 2H), 7.37 – 6.82 (m, 12H), 6.40 (d, 
J = 7.2, 1H), 6.34 (bs, 1H), 6.17 (bs, 1H), 5.02 (s, 2H), 4.30 (d, J = 7.1 Hz, 2H), 4.10 (t, J 
= 76.9 Hz, 1H), 3.96 (m, 4H), 3.30, (s, 1H), 3.23 – 3.11 (m, 1H) 2.60 – 2.50 (m, 8H, 2 
Pmc methyl groups, Arg δ methylene), 2.06 (s, 3H), 1.90 (s, 1H), 1.73 (t, J = 6.4 Hz, 2H), 
1.58 (bs, 2H), 1.44 (bs, 1H), 1.26 (s, 6H). 13C NMR (100 MHz, CDCl3) δ 169.8, 156.7, 
153.8, 148.3, 143.8, 141.3, 135.5, 135.3, 134.9, 128.7, 128.5, 128.4, 128.3, 127.8, 
127.2, 125.9, 125.3, 124.3, 120.0, 118.1, 73.8, 67.3, 67.2, 55.0, 47.1, 41.4, 34.0, 32.8, 
26.9, 26.9, 25.7, 25.5, 25.1, 21.6, 18.8, 17.7, 12.3, 11.5.  ESI+ MS calc for 
C46H54N6O9SNa [M+Na]+ 889.3571, found 889.3564.   
 (D)-(N-α-Fmoc-N-η-Pmc-argininyl)glycinylglycine benzyl ester (2.71 g, 3.1 mmol) 
was disolved in 45 mL of THF.  Piperidine (1.85 mL, 18.7 mmol) was added to the 
solution and the reaction was allowed to proceed at room temperature for 6 h.  Solvent 
was removed in vacuo and a silica column was run using a stepwise gradient of 5%, 
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10%, 20% and 25% MeOH in CHCl3 to afford pure deprotected tripeptide as a white 
solid (1.17 g, 60% over two steps).  Rf = 0.3 (25% MeOH/CHCl3). 1H NMR (500 MHz, 
CDCl3) δ 8.20 (bs, 1H), 7.62 (m, 1H), 7.32 – 7.23 (m, 5H), 6.44 (bs, 3H), 5.08 (s, 2H), 
4.06 – 3.90 (m, 4H), 3.51 (t, J = 6.8 Hz, 1H), 3.19 (s, 2H), 2.58 (dd, J = 6.6, 5.9 Hz, 2H), 
2.55 – 2.50 (m, 6H), 2.07 (s, 3H), 1.77 (dd, J = 8.9, 4.8 Hz, 3H), 1.58 (s, 3H), 1.28 (s, 
6H).  13C NMR (125 MHz, CDCl3) δ 176.0, 170.2, 169.9, 156.5, 153.6, 135.4, 135.2, 
134.7, 133.3, 128.6, 128.4, 128.2, 124.1, 118.0, 73.6, 67.1, 54.4, 42.7, 41.3, 32.8, 31.8, 
26.8, 25.4, 21.4, 18.5, 17.5, 12.2.  ESI+ MS calc for C31H45N6O7S [M+H]+ 645.3065, 
found 645.3089. 
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(D)-2,3-bis(dibenzyloxy)benzoyl(N-η-Pmc-argininyl)glycinylglycine benzyl ester.  
2,3-bis(dibenzyloxy)benzoic acid (0.143 g, 0.43 mmol), DCC (0.104 g, 0.5 mmol) and 
HOBt (0.068 g, 0.5 mmol) were taken up in 2.3 mL DCM and the OBt ester was allowed 
to form over 30 min.  At the same time, the (D)-(N-α-Fmoc-N-η-Pmc-arginin-
yl)glycinylglycine benzyl ester (0.250 g, 0.39 mmol) was taken up in 2.3 mL DCM to 
which 406 µL of DIPEA was added and allowed to stir.  After 30 min, the 
tripeptide/DIPEA mixture was transferred to the flask containing 2,3-
bis(dibenzyloxy)benzoyl-OBt ester and the reaction was allowed to proceed for 2 h at 
room temperature.  The mixture was then dried in vacuo and a silica column run using a 
stepwise gradient of 0%, 5% and 10% IPA in DCM to give the tetrapeptide product as a 
white solid (0.305 g, 82%).  Rf = 0.7 (20% IPA/CHCl3). 1H NMR (500 MHz, CDCl3) δ 8.48 
(d, J = 6.1 Hz, 1H), 7.70 (t, J = 5.8 Hz, 1H), 7.60 (bs, 1H), 7.53 (dd, J = 7.9, 1.5 Hz, 1H), 
7.45 – 7.19 (m, 15H), 7.11 (dd, J = 8.2, 1.5 Hz, 1H), 7.04 (t, J = 8.0 Hz, 1H), 6.29 (bs, 
2H), 6.10 (bs, 1H), 5.15 (d, J = 10.4 Hz, 1H), 5.11 (s, 2H), 5.08 (d, J = 10.4, 1H), 5.04 (s, 
2H), 4.45 (dd, J = 14.3, 5.5 Hz, 1H), 4.41 (d, J = 8.0 Hz, 1H ), 4.05 – 3.81 (m, 5H),  3.10 
(s, 1H), 3.04 – 3.95 (m, 1H), 2.56 (t, J = 6.69, 2H), 2.54 (s, 3H), 2.53 (s, 3H), 2.06 (s, 
3H), 1.86 (d, J = 3.2 Hz, 1H), 1.74 (t, J = 6.8 Hz, 2H), 1.66 (dd, J = 11.5, 6.0 Hz, 2H), 
1.35 (s, 3H), 1.26 (bs, 6H).  13C NMR (125 MHz, CDCl3) δ 172.8, 170.2, 169.8, 166.1, 
156.5, 153.7, 151.9, 147.2, 136.4, 136.4, 135.6, 135.5, 135.0, 133.6, 129.1, 128.9, 
128.8, 128.7, 128.5, 128.4, 128.3, 127.9, 126.6, 124.5, 124.1, 123.0, 118.1, 117.7, 76.4, 
73.7, 71.5, 67.1, 64.5, 54.0, 49.3, 43.1, 41.5, 34.0, 33.0, 28.9, 26.9, 26.9, 25.8, 25.5, 
25.3, 25.1, 21.6, 18.7, 17.6, 12.3.  ESI+ MS calc for C52H60N6O10SNa [M+Na]+ 983.3989, 
found 983.3968. 
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(D)-2,3-bis(dibenzyloxy)benzoyl(N-η-Pmc-argininyl))glycinylglycine (3).  (D)-2,3-
bis(dibenzyloxy)benzoyl(N-η-Pmc-argininyl))glycinylglycine benzyl ester (2.19 g, 2.3 
mmol) was disolved in 122 mL of MeOH.  30 mL of 5 M NaOH was then added to the 
solution and the reaction was allowed to proceed for 5 h at room temperature.  Organic 
solvent was then removed in vacuo.  The aqueous residue was then diluted with DI H2O 
and the solution was acidified to pH 2 with 3 M HCl, at which point the protonated acid 
precipitated from solution, affording the saponified tetrapeptide as a white solid (1.95 g, 
98%).  Rf = 0.7 (25% MeOH/DCM). 1H NMR (500 MHz, CDCl3) δ 8.51 (s, 1H), 7.97 (bs, 
1H), 7.79 (bs, 1H), 7.52 (d, J = 7.2 Hz, 1H), 7.43 – 7.28 (m, 7H), 7.17 (bs, 3H), 7.08 (d, J 
= 7.7 Hz, 1H), 7.03 (t, J = 7.8 Hz, 1H), 6.32 (bs, 2H), 6.21 (bs, 1H), 5.09 (d, J = 10.4 Hz, 
1H), 5.05 (2, 2H), 5.00 (d, J = 10.4 Hz, 1H), 4.44 (bs, 1H), 4.06 – 3.72 (m, 4H), 3.02 (bs, 
1H), 2.93 (bs, 1H), 2.53 (t, J = 6.1 Hz, 2H), 2.49 (s, 3H), 2.48 (s, 3H), 2.04 (s, 3H), 1.95 – 
1.83 (m, 1H), 1.72 (t, J = 6.5 Hz, 2H), 1.65 – 1.55 (m, 2H), 1.25 (s, 3H), 1.24 (s. 3H). 13C 
NMR (125 MHz, CDCl3) δ 173.0, 170.9, 166.0, 156.3, 153.5, 151.7, 147.0, 136.3, 136.2, 
135.5, 134.8, 128.9, 128.7, 128.6, 128.2, 127.7, 126.1, 124.4, 124.0, 122.9, 117.9, 
117.6, 104.2, 76.2, 73.6, 71.3, 63.8, 53.8, 49.2, 42.8, 41.7, 40.1, 34.0, 32.8, 28.8, 26.8, 
25.6, 24.9, 21.4, 18.5, 17.9, 17.5, 15.4, 12.1.  ESI+ MS calc for C45H54N6O10SNa [M+Na]+ 
893.3514, found 893.3486. 
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(L)-N-Boc-5-hydroxynorvaline benzyl ester (7).  (L)-N-Boc-glutamic acid benzyl ester 
(4.0 g, 11.9 mmol) was taken up in 57 mL of THF and cooled to -15 ºC in a bath of dry 
ice and ethylene glycol.  N-methylmorpholine (1.31 mL, 11.9 mmol) was added followed 
by dropwise addition of isobutyl chloroformate (1.56 mL, 11.9 mmol).  After stirring for 10 
min, sodium borohydride (1.35 g, 35.6 mmol) was added, followed by the slow addition 
of 117 mL of MeOH.  The mixture was allowed to stir for 10 min at -15 ºC following 
complete addition of MeOH.  This was followed by an additional 10 min at room 
temperature.  24 mL of 1N HCl was then added slowly to the mixture.  Organic solvents 
were removed in vacuo after complete addition of 1N HCl and the resulting aqueous 
solution was extracted three times with EtOAc.  The combined organic layers were 
washed once with 1N HCl, twice with DI H2O, once with 5% NaHCO3, three times with DI 
H2O and then dried with anhydrous Na2SO4.  The resulting clear, light-yellow oil was 
used without further purification (3.87 g, theoretical yield: 3.84 g).  Rf = 0.4 (1:1 
hexanes:EtOAc).  1H NMR (400 MHz, CDCl3) δ 7.41 – 7.25 (m, 5H), 5.48 (d, J = 8.0 Hz, 
1H), 5.14 (2d, J = 12.4 Hz, 2H), 4.39 – 4.27 (m, 1H), 3.57 (t, J = 6.2 Hz, 2H), 1.89 (m, 
1H), 1.72 (m, 1H), 1.58 (m, 2H), 1.43 (bs, 9H).  13C NMR (125 MHz, CDCl3) δ 172.7, 
155.6, 135.5, 128.6, 128.4, 128.2, 79.9, 67.0, 62.0, 59.2, 29.2, 28.3, 27.2.  ESI+ MS calc 
for C17H25NO5Na [M+Na]+ 346.1630, found 346.1641. 
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(L)-N-Boc-5-Iodonorvaline benzyl ester (8).  (L)-N-Boc-5-bromonorvaline benzyl ester 
(1.45 g, 3.8 mmol) was dissolved in 37.5 mL acetone.  NaI (2.81 g, 18.8 mmol) was 
added and the reaction refluxed at 70 ºC for 1 h.  The reaction was then filtered and the 
material was absorbed onto silica gel via solvent removal in vacuo.  The silica was then 
loaded onto a column and the product purified (30% EtOAc/hexanes) to provide a clear, 
light-pink oil (1.30 g, 80%).  Rf = 0.6 (30% EtOAc/hexanes). 1H NMR (500 MHz, CDCl3) ) 
δ 7.45-7.30 (m, 5H), 5.18 (2d, J = 12.2 Hz, 2H), 5.05  (d, J = 7.4 Hz, 1H), 4.37 (dd, J = 
12.3, 7.2 Hz, 1H), 3.20-3.10 (m, 2H), 2.02-1.68 (m, 4H), 1.43 (bs, 9H).  13C NMR (125 
MHz, CDCl3) δ 172.4, 155.4, 135.4, 128.9, 128.8, 128.7, 128.6, 128.4, 80.2, 67.8, 67.3, 
67.1, 66.7, 66.3, 52.9, 52.7, 33.9, 29.3, 28.5, 5.5.  ESI+ MS calc for C17H24NO4INa 
[M+Na]+ 456.0642, found 456.0654. 
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(L)-N-Boc-5-bromonorvaline benzyl ester (9).  (L)-N-Boc-5-hydroxynorvaline benzyl 
ester (3.87 g, 11.8 mmol) was taken up in 80 mL of DCM and the solution was cooled to 
-5 ºC with a bath of ice water and ammonium chloride.  At the same time, a solution of 
triphenylphosphine (6.30 g, 24.0 mmol) in 40 mL of DCM was prepared and similarly 
cooled to -5 ºC.  Under the exclusion of light, carbon tetrabromide (7.96 g, 24.0 mmol) 
was then added to the stirring (L)-N-Boc-5-hydroxynorvaline benzyl ester.  The dissolved 
triphenylphosphine was then added dropwise to this mixture and the reaction was 
allowed to slowly warm to room temperature over 2 h.  The solvents were then removed 
in vacuo in the presence of silica gel.  The silica was then dry-loaded onto a silica 
column and the product purified in 30% EtOAc/hexanes to afford a clear, colorless oil 
(2.68 g, 58%, two steps).  Rf = 0.2 (10% EtOAc/hexanes).  1H NMR (400 MHz, CDCl3) δ 
7.44 – 7.23 (m, 5H), 5.17 (2d, J = 12.3 Hz, 2H, benzylic; 1H, Boc-NH), 4.42 – 4.32 (m, 
1H), 3.48 – 3.22 (m, 2H), 2.08 – 1.67 (m, 4H), 1.43 (s, 9H).  13C NMR (125 MHz, CDCl3) 
δ 172.2, 155.3, 135.2, 128.7, 128.6, 128.6, 128.5, 128.3, 80.2, 67.3, 56.7, 32.7, 31.4, 
28.5, 28.3. ESI+ MS calc for C17H24NO4BrNa [M+Na]+ 408.0786, found 408.0792. 
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(L)-N-Boc-5-(O-p-toluenesulfonyl)hydroxynorvaline benzyl ester (10). (L)-N-Boc-5-
hydroxynorvaline benzyl ester was dissolved in 21 mL of pyridine and cooled to 0 ºC in a 
bath of ice and water.  p-toluenesulfonyl chloride (0.707 g, 3.7 mmol) was then added to 
the stirring mixture and the reaction was allowed to progress for 4 h while warming to 
room temperature.  After 4 h, the reaction was diluted with 100 mL of EtOAc and 
extracted twice with 1 N HCl and once with brine.  The EtOAc was dried with MgSO4, 
filtered and concentrated to dryness in vacuo.  A silica column (1:1 EtOAc:hexanes) was 
then run to give the product (0.585 g, 40%).  Rf = 0.7 (1:1 EtOAc:hexanes). 1H NMR 
(500 MHz, CDCl3) δ 7.76 (d, 8.17 Hz, 2H), 7.41-7.30 (m, 7H), 5.16 (2d, J = 12.1 Hz, 2H), 
5.02 (d, J = 7.7 Hz, 1H), 4.28 (dd, 13.8, 7.5 Hz, 1H), 4.05-3.95 (m, 2H), 2.44 (s, 3H), 
1.92-1.83 (m, 1H), 1.75-1.60 (m, 3H), 1.42 (s, 9H).  13C NMR (125 MHz, CDCl3) δ 172.2, 
155.4, 145.0, 135.3, 133.1, 130.0, 128.8, 128.7, 128.5, 128.0, 80.2, 69.8, 67.4, 53.0, 
31.1, 29.1, 28.4, 25.1, 21.8. 
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(L)-N-α-Boc-N-δ-benzyloxyornithine benzyl ester (13).  O-benzylhydroxylamine (73.7 
mg, 0.46 mmol) was taken up in 2.3 mL of dry DMF.  To this was added sodium hydride 
(36.9 mg, 0.92 mmol).  The mixture was allowed to stir for 10 min at room temperature. 
(L)-N-Boc-5-Iodonorvaline benzyl ester (0.200 g, 0.46 mmol) was dissolved in an 
additional 2.3 mL of dry DMF and added to the stirring mixture.  The reaction was heated 
to 85 ºC for 4 h.  The reaction was terminated by addition of DI H2O.  The aqueous 
solution was extracted four times with Et2O.  The combined ethereal extract was washed 
once with DI H2O, dried with anhydrous MgSO4 and concentrated to dryness in vacuo.  
A silica column was run using a stepwise gradient of 20% - 30% EtOAc/hexanes.  Rf = 
0.5 (30% EtOAc/hexanes).  Spectral analysis revealed that the isolated product was 
most likely to be the cyclization product (L)-1-(t-butoxycarbonyl)-3-(benzyloxy-
carbonylamino)piperdin-2-one (14). 1H NMR (500 MHz, CDCl3) δ 7.37-7.32 (m, 5H), 5.25 
(d, J = 12.5 Hz, 1H), 5.18 (d, J = 12.1 Hz, 1H), 5.13 (d, J = 12.1, 1H), 5.09 (d, J = 12.5 
Hz, 1H), 4.39 (dd, J = 8.7, 3.4 Hz, 1H), 4.27 (dd, J = 8.7, 3.9 Hz, 1H), 3.60-3.35 (m, 2H), 
2.28-2.12 (m, 1H), 2.03-1.39 (m, 3H), 1.46 (s, 3H), 1.35 (s, 6H). 13C NMR (125 MHz, 
CDCl3) δ 173.2, 173.0, 154.6, 154.0, 136.1, 135.8, 128.8, 128.7, 128.6, 128.5, 128.4, 
128.3, 128.2, 128.1, 80.1, 79.9, 66.8, 66.4, 66.0, 65.7, 59.4, 59.3, 59.2, 58.9, 47.0, 46.9, 
46.8, 46.5, 46.4, 46.3, 46.1, 46.0, 45.9, 45.4, 31.1, 30.1, 28.7, 28.6, 28.5, 28.4, 24.5, 
23.8.   
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(L)-N-α-Boc-serinyl-3-(O-benzyl)-1-O-benzylhydroxamate (15).  (L)-N-α-Boc-3-(O-
benzyl)serine (5.00 g, 16.9 mmol) and HOBt (2.74 g, 20.3 mmol) were taken up in 42 mL 
THF and the mixture was cooled to 0 ºC.  DCC (4.19 g, 20.3 mmol) was then added to 
the cooled mixture and the OBt ester was allowed to form.  Simultaneously, O-
benzylhydroxylamine (3.24 g, 20.3 mmol) was taken up in 120 mL 1:1 DCM:THF and 
then DIPEA (7.07 mL, 40.6 mmol) was added to the stirring mixture.  After 10 min, the 
O-benzylhydroxylamine/DIPEA mixture was added dropwise to the freshly prepared (L)-
N-α-Boc-3-(O-benzyl)serine-OBt ester.  The reaction was run for 24 h and allowed to 
slowly warm to room temperature.  After 24 h, the reaction was concentrated in vacuo.  
Diethyl ether was added to the resulting solid and the slurry was filtered through a plug 
of celite.  The filtrate was washed twice with 0.2 M citric acid, once with 5% NaHCO3 and 
three times with 0.4 M NaOH.  The combined NaOH layers were washed once with 
diethyl ether, acidified to pH 6.7 with 0.2 M citric acid and extracted twice with DCM.  
The combined organic layers were dried with anhydrous MgSO4 and concentrated in 
vacuo to afford the product as a white powder (5.75 g, 85%).  Rf = 0.7 (10% IPA/CHCl3). 
1H NMR (500 MHz, CDCl3) δ 9.16 (s, 1H), 7.45 – 7.18 (m, 10H), 5.38 (bs, 1H), 4.88 (s, 
2H), 4.47 (2d, J = 11.7 Hz, 2H), 4.34 – 4.17 (bs, 1H), 3.78 (dd, J = 9.2, 4.4 Hz, 1H), 3.52 
(bdd, J = 9.2 Hz, 1H), 1.48 – 1.34 (m, 9H). 13C NMR (125 MHz, CDCl3) δ 168.2, 155.4, 
137.2, 135.1, 129.2, 128.7, 128.5, 128.5, 128.3, 128.3, 128.2, 127.9, 127.8, 127.7, 80.4, 
78.3, 73.4, 69.5, 52.2, 28.3.  ESI+ MS calc for C22H29N2O5 [M+H]+ 401.2077, found 
401.2072. 
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(L,L)-N-α-Boc-N-δ-benzyloxy-N-δ-[N-α-Boc-3-(O-benzyl)serinyl]-ornithine benzyl 
ester (16).  (L)-N-α-Boc-serinyl-3-(O-benzyl)-1-O-benzylhydroxamate (1.22 g, 3.0 
mmol), K2CO3 (1.38 g, 10 mmol), and KI (0.168 g, 1.0 mmol) were taken up in 20 mL of 
anhydrous acetone, stirred and heated to 70 ºC.  After 10 min, (L)-N-Boc-5-
bromonorvaline benzyl ester (0.977 g, 2.5 mmol) was dissolved in 30 mL of anhydrous 
acetone and added dropwise to the refluxing solution.  The reaction was run for 24 h at 
70 ºC.  The suspension was then filtered and the acetone removed in vacuo.  The 
residue was dissolved in Et2O, which was extracted twice with 0.5 N NaOH, once with 
brine, dried over MgSO4, filtered and concentrated to dryness in vacuo.  A silica column 
was run using a stepwise gradient of 20%, 30% and 40% EtOAc in hexanes to afford the 
N-alkylated product as a clear, colorless oil (0.669 g, 37%).  Rf = 0.2 (30% 
EtOAc/hexanes). 1H NMR (500 MHz, CDCl3) ) δ 7.46-7.14 (m, 15H), 5.51-5.37 (d, J = 
7.34 Hz, 1H), 5.09 (2d, J = 12.3 Hz, 2H, benzylic; Boc-NH, 1H), 4.95 (bs, 1H), 4.86 
(overlapping d, J = 10.2 Hz, 2H), 4.42 (2d, J = 12.2 Hz, 2H), 4.33-4.26 (m, 1H), 3.99-
3.82 (m, 1H), 3.63 (2dd, J = 9.6, 4.8 Hz, 2H), 3.49-3.34 (m, 1H), 1.90-1.73 (m, 1H), 1.73-
1.51 (m, 2H), 1.62-1.52 (m, 1H), 1.44 (s, 9H), 1.41 (s, 9H).  13C NMR (125 MHz, CDCl3) 
δ 172.4, 171.1, 155.5, 137.8, 135.4, 134.1, 129.4, 129.3, 129.1, 128.8, 128.7, 128.4, 
128.3, 127.9, 127.7, 127.7, 79.9, 79.8, 77.0, 73.0, 69.8, 67.1, 53.4, 51.3, 45.1, 29.6, 
28.5, 23.1.  DART+ MS calc for C39H52N3O9 [M+H]+ 706.3704, found 706.3684. 
  The O-alkylated regioisomer of (L,L)-N-α-Boc-N-δ-benzyloxy-N-δ-[N-α-Boc-3-(O-
benzyl)serinyl]-ornithine benzyl ester (17) was also isolated as a white solid (0.530 g, 
30%).  Rf = 0.5 (30% EtOAc/hexanes). 1H NMR (500 MHz, CDCl3) ) δ 7.39-7.22 (m, 
15H), 5.21-5.06 (m, 3H), 5.03 (bd, J = 8.0 Hz, 1H), 4.95 (2d, J = 12.5 Hz, 2H), 4.48 (2d, 
J = 12.0 Hz, 2H), 4.42-4.35 (m, 1H), 4.35-4.24 (m, 2H), 4.23-4.15 (m, 1H), 3.64-3.53 (m, 
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2H), 2.27-2.13 (m, 1H) 2.02-1.89 (m, 1H), 1.89-1.77 (m, 1H), 1.67-1.54 (m, 2H), 1.43(bs, 
18H).  13C NMR (125 MHz, CDCl3) δ 173.2, 172.5, 155.5, 155.3, 153.9, 152.8, 138.0, 
137.7, 135.8, 135.5, 128.7, 128.6, 128.5, 128.5, 128.4, 128.4, 128.4, 128.4, 128.3, 
128.2, 128.1, 127.9, 127.8, 127.8, 127.7, 80.0, 79.8, 76.6, 73.2, 71.5, 70.2, 67.1, 66.7, 
59.3, 59.0, 53.4, 51.4, 46.7, 46.5, 31.0, 30.0, 29.0, 28.5, 28.4, 26.2, 24.4, 23.7.  DART+ 
MS calc for C39H52N3O9 [M+H]+ 706.3704, found 706.3729. 
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(L,L)-N-δ-benzyloxy-N-δ-[3-(O-benzyl)serinyl]-ornithine benzyl ester (4). (L,L)-N-α-
Boc-N-δ-benzyloxy-N-δ-[N-α-Boc-3-(O-benzyl)serinyl]-ornithine benzyl ester (0.669 g, 
0.95 mmol) was dissolved in 5 mL TFA and stirred for 5 min.  The TFA was then 
removed in vacuo.  The dry residue was then dissolved in DCM and extracted twice with 
5% NaHCO3.  The combined acqueous layers were washed once with DCM and the 
pooled organic layers dried, first with brine and then with anhydrous MgSO4.  The dried 
organic extract was then filtered and concentrated in vacuo.  The residue was then taken 
up in a small amount of DCM and applied to a silica plug.  The plug was rinsed with 3 
volumes of DCM and the deprotected peptide was then eluted in 20% IPA/DCM as a 
clear, colorless oil (0.479 g, 52%).  Rf = 0.4 (20% IPA/DCM). 1H NMR (500 MHz, CDCl3) 
δ 7.40-7.22 (m, 15H), 5.12 (overlapping d, J = 12.3 Hz, 2H), 4.81 (2d, J = 10.4 Hz, 2H), 
4.47 (2d, J = 12.1 Hz, 2H), 4.03 (bt, J = 5.1 Hz, 1H), 3.81-3.73 (m, 1H), 3.59 (dd, J = 9.0, 
5.6 Hz, 1H), 3.60-3.53 (m, 1H), 3.48 (dd, J = 9.1, 6.5 Hz, 1H), 3.45 (dd, J = 8.0, 4.7 Hz, 
1H), 1.79-1.66 (m, 3H), 1.64-1.48 (m, 7H).  13C NMR (125 MHz, CDCl3) δ 175.6, 174.5, 
138.0, 135.7, 134.2, 129.3, 129.1, 128.8, 128.6, 128.4, 128.4, 128.3, 127.7, 127.7, 76.6, 
73.2, 72.5, 66.7, 54.1, 51.6, 44.9, 31.7, 23.1.  ESI+ MS calc for C29H36N3O5 [M+H]+ 
506.2649, found 506.2636. 
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Fuscachelin B-(Bn)7(Pmc)2 (18).  (D)-2,3-bis(dibenzyloxy)benzoyl(N-η-Pmc-arginin-
yl))glycinylglycine (0.296 g, 0.34 mmol) and HOBt (0.051 g, 0.37 mmol) were dissolved 
in 3.4 mL THF and cooled in a bath of ice and water.  DCC ( 0.077 g, 0.37 mmol) was 
then added to the stirring solution and the OBt ester was allowed to form over 10 min.  
DIPEA (0.355 mL, 2.0 mmol) and (L,L)-N-δ-benzyloxy-N-δ-[3-(O-benzyl)serinyl]-ornithine 
benzyl ester (0.086 g, 0.17 mmol, dissolved in 3.4 mL THF) were added in succession.  
The reaction was allowed to warm to room temperature.  After 2 h, an additional 
equivalent of DCC (0.035 g, 0.17 mmol) and HOBt (0.023 g, 0.17 mmol) were added.  
The reaction was then run for 12 h, at which point, one more equivalent of both DCC and 
HOBt were added.  The reaction was run for an additional 2 h.  The insoluble 
dicyclohexylurea byproduct was removed via filtration through fine pore filter paper.  THF 
was removed in vacuo and a silica column was run using a stepwise gradient of 0%, 5%, 
10% 15%, 20% and 25% IPA in DCM to afford the fully protected decapeptide as a white 
solid (0.185 g, 49%).  Rf = 0.8 (20% IPA/DCM). 1H NMR (500 MHz, CDCl3) ) δ 8.56-8.38 
(m, 2H), 7.61-7.52 (m, 2H), 7.48-7.14 (m, 38H), 7.13-7.03 (m, 4H), 6.48-6.01 (m, 5H), 
5.23-4.95 (m, 12H), 4.90-4.78 (m, 3H), 4.57-4.50 (m, 1H), 4.50-4.34 (m, 4H), 4.34-4.29 
(m, 1H), 4.28-4.18 (m, 1H), 4.07-3.32 (m, 16H), 3.20-2.85 (m, 4H), 2.62-2.49 (m, 14H), 
2.07 (s, 6H), 1.79-1.49 (m, 12H), 1.26 (s, 12H).  13C NMR (125 MHz, CDCl3) δ 175.4, 
175.1, 173.3, 173.0, 171.8, 171.3, 170.5, 170.0, 169.7, 169.0, 165.9, 165.8, 156.3, 
153.5, 151.7, 147.0, 137.4, 136.2, 135.4, 134.7, 134.0, 133.4, 129.3, 129.0, 128.9, 
128.9, 128.9, 128.7, 128.6, 128.6, 128.5, 128.3, 128.2, 128.2, 128.2, 128.0, 127.6, 
126.1, 124.4, 123.9, 122.9, 122.9, 117.8, 117.5, 117.5, 76.2, 73.5, 73.0, 71.3, 69.4, 68.7, 
66.9, 66.6, 64.3, 54.1, 53.8, 49.9, 49.5, 49.3, 49.1, 45.0, 44.7, 44.6, 43.1, 43.0, 39.9, 
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32.7, 26.7, 25.3, 21.4, 18.5, 17.4, 12.1.  ESI+ MS calc for C119H139N15O23S2Na [M+Na]+ 
2232.9507, found 2232.9511. 
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Fuscachelin B (2).  18 (0.155 g, 70 µmol) was taken up in 5 mL of a solution of 95:5:0.1 
TFA:H2O:thioanisole and stirred at room temperature for 2.5 h.  The liquid was then 
removed in vacuo and the residue dissolved in water and lyophilized.  Then, 10 mg of 
the freeze dried material was dissolved in 1.5 mL of 25 % MeOH/ glatial acetic acid (v/v), 
15 mg of Pd black was added and the vessel was purged with dry nitrogen for 10 min.  
The slurry was then purged with hydrogen gas (balloon conditions, ambient temperature 
and pressure) for 16 h.  The Pd black was pelleted at 13,000 rpm for 1 min using an 
Eppendorf centrifuge 5417C equipped with an F45-30-11 rotor.  The supernatant was 
collected and evaporated in vacuo, the residue dissolved in water and the material 
lyophilized.  The freeze dried solid was then taken up in 1 mL of 23% MeOH/ 0.1 % TFA 
(v/v) water and applied to a Vydac 218TP1022 Protein and Peptide C18 column (250 x 
22 mm, 10 µm) on a Shimadzu LC-6AD liquid chromatography system equipped with a 
Shimadzu SPD-10A UV-Vis detector.  A detection wavelength of 320 nm was chosen to 
monitor elution of the 2,3-dihydroxybenzoyl moiety.  Two, 500 µL portions were injected 
onto the column and purified using a linear gradient of 23-28% methanol in water/0.1% 
TFA over 30 min at 8 mL min-1.  The material was collected at 17 min. Methanol was 
removed by rotary evaporation and the aqueous solution was dried by lyophilization to 
afford the peptide as a white solid (530 µg, 9%).  MALDI+ MS calc for C42H62N15O17 
[M+H]+ 1048.4448, found 1048.4431. 
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Fuscachelin A (1).  2 mg of fuscachelin B (1.9 µmol) was taken up in 1.178 mL of dry 
DMF.  To this solution was added EDC (3.8 µmol, 38 µL from a freshly prepared 100 
mM solution in dry DMF) and DMAP (5.7 µmol, 57 µL from a freshly prepared 100 mM 
solutionin dry DMF).  The mixture was gently agitated at room temperature for 36 h.  At 
12 h and 24 h, an additional equivalent of EDC (19 µL, 100 mM stock) and DMAP (19 
µL, 100 mM stock) was added to the mixture.  The reaction was terminated by flash 
freezing in liquid nitrogen.  The solvent was then removed via lyophilization.  The 
product was purified by preperative HPLC using a Vydac 218TP1022 Protein and 
Peptide C18 column (250 x 22 mm, 10 µm) on a Shimadzu LC-6AD liquid 
chromatography system equipped with a Shimadzu SPD-10A UV-Vis detector.  A 
detection wavelength of 320 nm was chosen to monitor elution of the 2,3-
dihydroxybenzoyl moiety. The lyophilized material was dissolved in 500 µL of 23% 
methanol/ 0.1% TFA (v/v) water.  Two, 250 µL portions were injected onto the column 
and purified using a linear gradient of 23-28% methanol in 0.1% TFA (v/v) water over 30 
min at 8 mL min-1.  The material was collected at 22 min.  Methanol was removed by 
rotary evaporation and the aqueous solution was dried by lyophilization to afford the 
peptide as a white solid (1.47 mg, 75%).  LCQ ESI+ MS calc for C42H60N15O16 [M+H]+ 
1030.4, found 1030.5.  LCQ ESI+ MS calc for C42H61N15O16 [M+2H]2+ 515.7, found 515.9.  
LCQ ESI+ MS calc for C42H57N15O16Fe [M-2H+Fe3+]+ 1083.3, found 1083.4. LCQ ESI+ 
MS calc for C42H58N15O16Fe [M-H+Fe3+]2+ 542.2, found 542.3. 
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Fuscachelin A – Ga3+ complex (20).  This reaction was performed in a flask that had 
been washed with a 1:1 solution of HNO3 and dd H2O. To 8.6 mL of dd H2O was added 
97.1 µL of a 0.01 M fuscachelin A stock solution (1.0 mg, 0.97 µmol) and 971 µL of a 
0.01 M GaBr3 solution (3.00 mg, 9.7 µmol).  After 16 h, the reaction was flash frozen and 
lyophilized.  The complex was purified via HPLC (same equipment as stated above for 1 
and 2) using a linear gradient of 2-80% B in A (where buffer A is 5 mM ammonium 
acetate pH 6.5 and buffer B is methanol) over 30 min following an initial 3 min wash with 
2% B.  A flow rate of 10 mL min-1 and detection wavelengths of 220 and 320 nm were 
used.  The product eluted at 18 min.  Organic solvent was removed via rotary 
evaporation and water was removed via lyophilization to give the complex as a white 
solid (400 µg, 40%). MALDI+ MS calc for C42H57N15O16Ga [M+Ga]+ 1096.3358, found 
1096.1933. 
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Fuscachelin B – Ga3+ complex (21).  This reaction was performed in a flask that had 
been washed with a 1:1 solution of HNO3 and dd H2O.  To 8.6 mL of dd H2O was added 
9.5 µL of a 0.1 M fuscachelin B stock solution (1.0 mg, 0.95 µmol) and 950 µL of a 0.01 
M GaBr3 solution (2.96 mg, 9.5 µmol).  After 16 h, the reaction was flash frozen and 
lyophilized.  The complex was purified via HPLC (same equipment as stated above for 1 
and 2) using a linear gradient of 2-80% B in A (where buffer A is 5 mM ammonium 
acetate pH 6.5 and buffer B is methanol) over 30 min following an initial 3 min wash with 
2% B.  A flow rate of 10 mL min-1 and detection wavelengths of 220 and 320 nm were 
used.  The product eluted at 15 min.  Organic solvent was removed via rotary 
evaporation and water was removed via lyophilization to give the complex as a white 
solid (450 µg, 44%). MALDI+ MS calc for C42H59N15O17Ga [M+Ga]+ 1114.3464, found 
1114.3471. 
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The Fuscachelins – Past & Present 
 The genome of the thermophilic actinomycete Thermobifida fusca was 
sequenced in 2007.1  As was the case for other actinomycetes, perhaps most famously 
Streptomyces coelicolor, the completion of genomic sequencing holds the alluring 
prospect of new small molecule discovery.2-5  In a genome mining effort, we were able to 
identify a nonribosomal peptide synthetase (NRPS) gene cluster in T. fusca that 
appeared to code for the production of a novel siderophore natural product.  Attempts to 
isolate the secondary metabolite lead to the discovery of a unique set of decameric NRP 
natural products that we named fuscachelins.6  They stand as some of the only natural 
products isolated form thermophilic microorganisms and present a novel scaffold for the 
acquisition of iron(III).  The structures of the siderophores were corroborated by total 
synthesis and their ability to bind metal has been confirmed for both Fe3+ and Ga3+.   
 Structure elucidation of a natural product lays a foundation upon which all other 
studies of the biological and chemical attributes of the associated system may be built.  
This is particularly true for biosynthetic studies, where the structure of the small molecule 
provides the context, both chemical and biological, in which one may ask specific and 
detailed questions.  In the pages below, we will pose three important questions that were 
inspired by completion of the structure elucidation and synthesis of the fuscachelins:  
Can we gain a detailed mechanistic understanding of the NRP biosynthesis of the 
fuscachelins while at the same time utilizing the enzymes as practical biocatalysts?  
What can the fuscachelin system teach us about iron uptake and trafficking in 
microorganisms?  Lastly, can the scope of biological activity of the fuscachelins be 
extended beyond the realm of iron sequestration? 
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The Fuscachelin NRPS – Chemistry and Mechanism 
 The modularity and flexibility of NRPS systems has, for a long time, suggested 
that these enzymes could be used to solve unique and challenging synthetic problems.  
The concept of combinatorial biosynthesis has grown from the elegance of the 
“assembly line” model of NRP biosynthesis.7-10  Here, NRPS modules and domains are 
viewed as mobile components that can be rearranged, using the tools of genetic 
engineering, to produce custom-designed small-molecule-producing macromolecular 
machines.  In order to transform this conceptual framework into a concrete, practical 
system, structural and biochemical details of the enzyme components must be 
thoroughly understood.  Thus, some very basic and important questions can be posed.  
For instance, how do the smallest functional components of an NRPS, the domains, do 
their job?  How do they interact and communicate within the context of a full NRPS 
module?  The same can be asked about module-module interactions.  Chemical tools 
have been developed to address these fundamental mechanistic questions, and we will 
begin our exploration of this topic by examining some of them. 
Probing NRPS Chemistry with Coenzyme-A Inspired Small Molecules 
 As was discussed in chapter 1, an NRPS is not synthetically competent until it 
has been converted to its holo form via phosphopantetheinylation of its thiolation (T) 
domains.  The phosphopantetheinyl (PPT) tether is derived from coenzyme A (Fig. 4.1) 
and is loaded onto the T domain by a phosphopantetheinyl transferase (PPTase).  PPT-
aminoacyl and PPT-peptidyl, T-domain bound biosynthetic intermediates then serve as 
substrates for all of the other NRPS domains.  The centrality of CoA and the CoA-
derived PPT tether has inspired the development of a collection of synthetic tools used  
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to probe NRPS biosynthesis (Fig. 4.1, box).11, 12  It has been shown that synthetic CoA-
thioesters can be directly loaded onto apo T-domains by promiscuous PPTases 
(particularly the B. subtilis derived PPTase, Sfp).13-15  Using this methodology, NRP 
“mutants” can be prepared by introducing custom-designed, CoA-bound thioester 
substrates directly onto the synthetase16-18.  The desire to eliminate the cumbersome 
CoA component on these molecules inspired the development of the far more 
synthetically accessible N-acetylcysteamine (SNAc) derivatives (Fig. 4.1, box).12, 16  
These molecules mimic the thiol-containing terminus of CoA while eliminating the more 
complex nucleotide and pantothenate portions of the molecule.  Fortunately, SNAc 
derived thioesters serve as viable substrates for most systems.  The combined use of 
synthetic CoA and SNAc derived thioesters has shown, in many cases, that NRPS 
domains can be used as flexible chemoenzymatic tools.16 
Fig. 4.1    Coenzyme A (CoA)/amino-CoA and N-acetylcysteamine (SNAc)/N-acetylethylene-
diamine (NNAc) substrates of the fuscachelin NRPS termination module FscI.  All of these 
substrates can be derived from synthetic intermediates from the fuscachelin total synthesis. 
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 The use of the thioester tether in NRP biosynthesis (indeed, in other types of 
biosynthesis as well) is a reflection of the ability of evolution to balance kinetic efficiency 
with the thermodynamic demands of amide bond formation.  It follows that the 
introduction of a more stable acyl tether could be exploited as an effective inhibitor of 
NRPS systems.  This has led to the development of amino-CoA inhibitors (Fig. 4.1, box) 
of CoA and PPT-utilizing biosynthetic enzymes by Bruner and co-workers.11, 19  These 
have proven to be useful tools in the crystallographic and biochemical analysis of a 
number of NRPS-based enzymatic systems.  In some cases, it may prove easier to use 
the SNAc-inspired N-acetylethylenediamine (NNAc) derivatives of amino-CoA in similar 
investigations.  As is illustrated in Figure 4.1, there are several intermediates that 
appeared in the total synthesis of the fuscachelins that could be readily adapted for 
these types of investigations.   
 How then, can we use these tools to better understand or use the fuscachelin 
biosynthetic enzymes?  In an attempt to directly utilize NRPS enzymes as catalysts in 
chemoenzymatic synthesis, it has been established in many cases that thioesterase 
domains can be excised from an assembly line and utilized in vitro as macrocyclization 
catalysts.17, 18, 20, 21  Often, preparation of an SNAc as substrate is all that is required for 
successful catalysis.  As illustrated in Figure 4.2, we propose that the TE domain of FscI, 
the termination module in fuscachelin biosynthesis, be utilized as a chemoenzymatic 
catalyst for the preparation of fuscachelin A.  This would alleviate the need for the use of 
coupling reagents, including the strongly basic DMAP, in preparing the lactone.  We 
believe that this would also simplify purification of the parent natural product and would 
likely lead to the reduction of reaction time. 
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 In our studies of fuscachelin biosynthesis, some attention has already been given 
to the chemistry of the NRPS termination module, FscI (see chapter 2).  FscI performs a 
broad range of chemistry, which includes N-δ-hydroxyornithine (HOOrn) tethering and 
the subsequent coupling of the peptides DHB-Arg-Gly-Gly-Ser and DHB-Arg-Gly-Gly to 
the δ and α amines of the T-domain bound HOOrn.  We propose that FscI could be 
utilized to assemble fuscachelin A from HOOrn (which we have already prepared, see A-
domain assay, chapter 2) and the SNAc derivatives of the two aforementioned peptides.  
Of the two, DHB-Arg-Gly-Gly can be derived from a readily accessible intermediate in 
the fuscachelin total synthesis (see Materials and Methods below) as could the DHB-
Arg-Gly-Gly-Ser peptide.  This one-pot assembly of the parent natural product would 
greatly simplify the synthetic preparation of the fuscachelin peptides and would eliminate  
Fig. 4.2    Chemoenzymatic macrolactonization mediated by the FscI thioesterase using 
a fuscachelin B – SNAc as a substrate. 
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the greatest synthetic bottleneck, the global deprotection of fully protected fuscachelin B.  
The chemoenzymatic proposal is diagrammed in Figure 4.3. 
In addition to developing FscI as a synthetic tool, we are interested in gaining a 
more detailed understanding of the mechanism by which it performs its chemistry.  The 
macrolactone of fuscachelin A is likely to preorganize the siderophore into a three 
dimensional conformation that favors the facile formation of a ferrisiderophore complex.  
It is also probable that the macrocycle forces the hydroxamate into the cis conformation, 
which is necessary for successful bidentate chelation of the iron center.  It is reasonable 
to suggest then, that FscI binds this conformation in the process of marcolactonization 
(Fig. 4.4A).  We believe we could trap this interesting conformer in the enzyme active 
Fig. 4.3    Chemoenzymatic synthesis of fuscachelin A using FscI as a catalyst for peptide ass-
embly and macrocyclization.  SNAc derivatives of DHB-Arg-Gly-Gly (the product of FscG) and 
DHB-Arg-Gly-Gly-Ser (the product of FscG and FscH) can be used as substrates for the FscI C-
domain.  N-δ−hydroxyornithine can be prepared synthetically via an established protocol. 
 179 
site by treating FscI with an SNAc derivative of fuscachelin B (analogous to that shown 
in Fig. 4.1), where an alanine “mutation” is synthetically introduced at the serine position.  
The peptide would be transferred from the SNAc to the dedicated serine residue of the 
FscI TE domain, where it would remain, due to the lack of the side chain nucleophile of 
serine (Fig. 4.4B).  The structure of the enzyme/inhibitor complex could then be studied 
using crystallographic analysis.  The synthesis of the fuscachelin core dipeptide (Ser-
HOOrn) outlined in the previous chapter would be readily adaptable to the introduction of 
the alanine residue. 
Prior to lactonization, fuscachelin B must be transferred from the T-domain 
thioester to the serine of the TE domain.  This process is likely to involve global 
conformational changes in FscI to mediate peptide transfer between domains.  To date, 
the structural details of substrate transfer within full NRPS modules has remained 
Fig. 4.4   (A) FscI releases the fuscachelin A macrocycle via condensation of the side chain 
oxygen of serine upon the TE-bound ornithinyl ester.  (B)  A fuscachelin B derivative contain-
ing alanine in the place of serine could be used to inhibit peptide release via 
macrolactonization, providing a crystallographic snap shot of TE bound fuscachelin B. 
 180 
elusive.  We believe that an amino-CoA derivative of fuscachelin B (Fig. 4.1, X=NH) 
could be loaded onto the T domain of FscI using established PPTase chemistry.  Once 
tethered, transfer of the mature peptide to the TE domain would be inhibited due to the 
nonhydrolyzable nature of the amino-CoA amide linkage (Fig. 4.5).  We could thus trap 
FscI in its active conformation.  Crystallographic analysis of this important transition state 
would reveal details about the communication and recognition events that occur 
between NRPS domains within a complete NRPS termination module.   
 The proposals discussed above highlight the utility of developing a 
straightforward, flexible chemical synthesis of the fuscachelins.  We have proposed the 
strategic use of readily accessible synthetic intermediates to exploit or probe the 
chemistry of FscI, the termination module in fuscachelin biosynthesis.  From these 
Fig. 4.5    An amino-CoA derivative of fuscachelin B could be loaded onto Apo-FscI using 
a phosphopantetheinyl transferase (PPTase).  Once loaded, the amide linkage would 
prevent transfer of the peptide to the FscI TE.  Crystallographic analysis of this complex 
would reveal details about interdomain communication. 
 181 
experiments, we stand to gain useful chemoenzymatic tools as well as sought after 
knowledge regarding the mechanism and function of NRPS biosynthetic enzymes.  
Below, we will direct our attention to a non-biosynthetic component of the fsc gene 
cluster, focusing specifically on the use of the fuscachelins by T. fusca.   
Iron Acquisition in T. fusca 
 When an iron-charged siderophore is imported into a bacterial cell, the iron must 
be liberated from the ligand in order to be utilized or stored.  Because siderophores form 
such stable complexes, this process must be enzymatically mediated.22, 23  In most 
cases, the reduction of iron(III) to iron(II), catalyzed by an enzyme bound flavin cofactor, 
is sufficient to liberate iron from a siderophore.  A gene on the periphery of the 
fuscachelin biosynthetic cluster, at locus 1860, was annotated as a 34 kDa “iron-chelator 
utilization protein” and shared 43% identity with MxcB of the myxochelin cluster in S. 
aurantiaca.  The protein was predicted to have two domains; a flavin-binding domain and 
a siderophore-binding domain, as is found in other annotated iron-chelator utilization 
proteins.  We are interested in probing the iron uptake mechanism of T. fusca, and so 
gene tfu 1860 was cloned from T. fusca genomic DNA, introduced into an E. coli 
expression vector, overexpressed and purified (see Materials and Methods below).  The 
recognition and transport of iron-loaded siderophores by membrane transport systems 
has been investigated crystallographically.24, 25  Interestingly, the recognition and 
utilization events of cytoplasmic siderophore-metal complexes have received little 
attention.  Thus, we would like to shed light on this process by structurally characterizing 
a complex of the gene product of tfu 1860 with Ga3+ loaded fuscachelin.  This would 
reveal the important structural features required for recognition of a siderophore-metal 
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complex by siderophore utilization proteins.  Along these lines, it would be interesting to 
examine the structural changes that may occur in the metal charged siderophore when 
binding to an enzyme active site.  To make this comparison, we would need to know the 
three-dimensional solution structure of the fuscachelin-metal complex.  This can be 
achieved using standard NMR spectroscopic techniques.  Considering likely conformers 
of the Ga3+-fuscachelin complex, we believe that there should be abundant through-
space (NOE) interactions (especially within the macrocycle) in the peptide to afford an 
accurate structural solution (Fig. 4.6).   
 
The Fuscachelins – Beyond Iron Acquisition 
 In several instances, natural product isolation programs have isolated 
siderophores using assay guided fractionation strategies, where the activity assay was 
something other than affinity for iron (i.e. the CAS assay).  In these cases, a biologically 
active compound was isolated that, upon structure elucidation, ended up being a 
Fig. 4.6    The fuscachelin A-Ga(III) complex could be used to determine the solution structure 
of the metal-bound siderophore using NMR spectroscopy.  A co-complex of the Ga(III) loaded 
siderophore and the iron-chelator utilization protein (Tfu 1860) clustered with the fsc genes 
would reveal details of intracellular iron trafficking. 
 183 
siderophore only coincidentally.26-28  As in the case of madurastatin (Actinomadura 
madurae), the siderophore was isolated due to its antimicrobial activity.29  To this end, 
we are interested in exploring the possibility of antimicrobial activity in the fuscachelins.  
An agar plate, disk diffusion assay (akin to the Kirby-Bauer method, see Materials and 
Methods below) has been established which will be capable of probing the toxicity of the 
fuscachelins against other bacteria.30   
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Concluding Remark 
In this thesis, we have outlined the discovery of a unique class of microbial 
secondary metabolite siderophores, the fuscachelins.  The producing organism, 
Thermobifida fusca, is a member of the actinomycetes, the famous order of bacteria that 
contains some of the most prolific natural product producers known.  Of these, the 
thermophilic actinomycetes comprise only a small group.  As we have shown, they too 
contain interesting secondary metabolic potential.  Having thoroughly established 
methods for the production of the fuscachelins, both biologically and synthetically, and 
having confirmed their structures using multiple chemical and spectroscopic methods, 
the stage is now set to probe the details of the fuscachelin gene cluster further.  The 
more we learn about the mechanisms of NRPS biosynthesis, the closer we get to solving 
challenging biological, chemical and medical problems.  A consensus has seemed to 
emerge among scientists that the problems of the 21st century require cooperation and 
communication between disciplines.  It is the hope of the author that the work described 
here, which utilized tools from the biological, chemical and physical sciences, may serve 
as a foundation upon which future researchers may become purveyors of this modern 
consensus. 
 
 
 
 
 
 185 
Materials and Methods 
Preparation of (D)-2,3-(dihydroxy)benzoylargininylglycinylglycine.  (D)-2,3-bis(di-
benzyloxy)benzoyl(N-η-Pmc-argininyl))glycinylglycine (15 mg, 17 µmol) was dissolved in 
1.2 mL 5% (v/v) glatial acetic acid/ THF in a round bottom flask which was thoroughly 
flushed with a stream of dry nitrogen.  To this was added 10 mg of 10% Pd/C.  The 
vessel was flushed with hydrogen (ambient pressure, balloon conditions) for 6 h, at 
which point the Pd/C was removed via filtration through fine pore filter paper.  The filtrate 
was concentrated to dryness in vacuo.  The dry residue was then taken up in 5 mL of a 
solution of 95:5:0.1 TFA:H2O:thioanisole and stirred at room temperature for 2.5 h.  The 
liquid was then removed in vacuo and the residue dissolved in water and lyophilized.   
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Cloning, expression and purification of Tfu 1860.  The gene for Tfu 1860 was 
amplified using PCR from Thermobifida fusca genomic DNA with the following primers: 
5´ CTC CGT CAA GCG TCA CAC GGT TGC and 5´ CGA CTC CGG CGA TTC CGC 
GAA CGA.  The following nested primers were used to introduce HindIII and BamHI 
restriction sites into the gene: 5´ GCG AAG CTT CTA CTC GTC GTC ATC GTC 
(HindIII), 5´ GCG GGA TCC ATG ACC GCA ACC GTG ACG (BamHI).  The PCR 
products were purified through agarose gel electrophoresis and gel extraction (Qiagen) 
and cleaved with the HindIII and BamHI restriction endonucleases. The Tfu 1860 gene 
was then ligated into the plasmid pET28a.  The plasmid was transformed into E. coli 
BL21(DE3) cells for gene expression.  Cultures (1 L) were grown to O.D.600 = 0.5-0.7 at 
37 ºC, at which point the shaker was cooled to 18 ºC and overexpression was initiated 
by addition of 50 mM IPTG. Cultures were continued for 18 h and were harvested by 
centrifugation, followed by resuspension in 500 mM NaCl, 20 mM Tris-HCl (pH 7.5) and 
lysed by passage through a French Press Cell at 1000 psi.  Lysate was centrifuged at 
10,000 rpm for 20 min.  The supernatant was incubated for 1 h with 1 mL Ni-NTA metal 
affinity resin (QIAGEN). Resin was washed with one, 10 mL portion of 500 mM NaCl, 20 
mM Tris-HCl (pH 7.5) and protein was eluted with two, 10 mL portions of 500 mM NaCl, 
20 mM Tris-HCl (pH 7.5), 250 mM imidazole. Protein was dialyzed against 50 mM NaCl, 
20 mM Tris-HCl (pH 7.5), 1 mM β-mercaptoethanol, concentrated to 2 mL and submitted 
to further purification using gel filtration chromatography. 
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Agar Plate Disk Diffusion Assay for Antimicrobial Activity.  Experiments were 
performed on agar plates containing LB media and M9 media.  The plates were 
inoculated with 200 µL of E. coli that had been grown in 5 mL of LB for 5 h at 37 ºC.  The 
cells contained the plasmid pET 30, which confers kanamycin resistance.  6 mm paper 
disks were prepared from standard laboratory filter paper and were sterilized overnight 
under ultraviolet illumination.  Plates were allowed to dry briefly before the application of 
disks to the surface. 10, 40, 70 and 100 µg quantities of the test compound were applied 
to the paper disk in 10 µL quantities.  Three disks of identical concentration were applied 
to each plate (see diagram).  Plates were grown overnight at 37 ºC.   
A control experiment was run in which the disks contained either water, 
kanamycin or chloramphenicol.  As expected, the plates containing kanamycin and 
water showed no zones of inhibition.  The chloramphenicol plates did show zones of 
inhibition, where the size of the zone was dose dependent.  Plates tested with identical 
amounts of the fuscachelin peptides exhibited no zones of inhibition against this strain of 
E. coli.  
 
 
 
 
 
Agar Surface
Paper Disk
Zone of inhibition measured
through center of disk
Bacterial 
Colonies
 190 
References 
1. Lykidis, A.; Mavromatis, K.; Ivanova, N.; Anderson, I.; Land, M.; DiBartolo, G.; 
Martinez, M.; Lapidus, A.; Lucas, S.; Copeland, A.; Richardson, P.; Wilson, D. B.; 
Kyrpides, N., Genome sequence and analysis of the soil cellulolytic actinomycete 
Thermobifida fusca YX. J. Bacteriol. 2007, 189, (6), 2477-86. 
2. Bentley, S. D.; Chater, K. F.; Cerdeno-Tarraga, A. M.; Challis, G. L.; Thomson, 
N. R.; James, K. D.; Harris, D. E.; Quail, M. A.; Kieser, H.; Harper, D.; Bateman, 
A.; Brown, S.; Chandra, G.; Chen, C. W.; Collins, M.; Cronin, A.; Fraser, A.; 
Goble, A.; Hidalgo, J.; Hornsby, T.; Howarth, S.; Huang, C. H.; Kieser, T.; Larke, 
L.; Murphy, L.; Oliver, K.; O'Neil, S.; Rabbinowitsch, E.; Rajandream, M. A.; 
Rutherford, K.; Rutter, S.; Seeger, K.; Saunders, D.; Sharp, S.; Squares, R.; 
Squares, S.; Taylor, K.; Warren, T.; Wietzorrek, A.; Woodward, J.; Barrell, B. G.; 
Parkhill, J.; Hopwood, D. A., Complete genome sequence of the model 
actinomycete Streptomyces coelicolor A3(2). Nature 2002, 417, (6885), 141-7. 
3. Hopwood, D. A., Streptomyces in nature and medicine : the antibiotic makers. 
Oxford University Press: Oxford ; New York, 2007; p viii, 250 p., 8 p. of plates. 
4. Ikeda, H.; Ishikawa, J.; Hanamoto, A.; Shinose, M.; Kikuchi, H.; Shiba, T.; 
Sakaki, Y.; Hattori, M.; Omura, S., Complete genome sequence and comparative 
analysis of the industrial microorganism Streptomyces avermitilis. Nat. Biotech. 
2003, 21, (5), 526-31. 
5. Omura, S.; Ikeda, H.; Ishikawa, J.; Hanamoto, A.; Takahashi, C.; Shinose, M.; 
Takahashi, Y.; Horikawa, H.; Nakazawa, H.; Osonoe, T.; Kikuchi, H.; Shiba, T.; 
Sakaki, Y.; Hattori, M., Genome sequence of an industrial microorganism 
Streptomyces avermitilis: deducing the ability of producing secondary 
metabolites. Proc. Natl. Acad. Sci. U S A 2001, 98, (21), 12215-20. 
6. Dimise, E. J.; Widboom, P. F.; Bruner, S. D., Structure elucidation and 
biosynthesis of fuscachelins, peptide siderophores from the moderate 
thermophile Thermobifida fusca. Proc. Natl. Acad. Sci. U S A 2008, 105, (40), 
15311-6. 
7. Fischbach, M. A.; Walsh, C. T., Assembly-line enzymology for polyketide and 
nonribosomal Peptide antibiotics: logic, machinery, and mechanisms. Chem. 
Rev. 2006, 106, (8), 3468-96. 
8. Sattely, E. S.; Fischbach, M. A.; Walsh, C. T., Total biosynthesis: in vitro 
reconstitution of polyketide and nonribosomal peptide pathways. Nat. Prod. Rep. 
2008, 25, (4), 757-93. 
9. Walsh, C. T., Polyketide and nonribosomal peptide antibiotics: modularity and 
versatility. Science 2004, 303, (5665), 1805-10. 
10. Walsh, C. T., The chemical versatility of natural-product assembly lines. Acc. 
Chem. Res. 2008, 41, (1), 4-10. 
11. Liu, Y.; Bruner, S. D., Rational manipulation of carrier-domain geometry in 
nonribosomal peptide synthetases. ChemBioChem 2007, 8, (6), 617-21. 
12. Meier, J. L.; Burkart, M. D., Chapter 9. Synthetic probes for polyketide and 
nonribosomal peptide biosynthetic enzymes. Methods Enzymol 2009, 458, 219-
54. 
13. Quadri, L. E.; Weinreb, P. H.; Lei, M.; Nakano, M. M.; Zuber, P.; Walsh, C. T., 
Characterization of Sfp, a Bacillus subtilis phosphopantetheinyl transferase for 
 191 
peptidyl carrier protein domains in peptide synthetases. Biochemistry 1998, 37, 
(6), 1585-95. 
14. Reuter, K.; Mofid, M. R.; Marahiel, M. A.; Ficner, R., Crystal structure of the 
surfactin synthetase-activating enzyme sfp: a prototype of the 4'-
phosphopantetheinyl transferase superfamily. EMBO J 1999, 18, (23), 6823-31. 
15. Mofid, M. R.; Finking, R.; Marahiel, M. A., Recognition of hybrid peptidyl carrier 
proteins/acyl carrier proteins in nonribosomal peptide synthetase modules by the 
4'-phosphopantetheinyl transferases AcpS and Sfp. J. Biol. Chem. 2002, 277, 
(19), 17023-31. 
16. Tseng, C. C.; Bruner, S. D.; Kohli, R. M.; Marahiel, M. A.; Walsh, C. T.; Sieber, S. 
A., Characterization of the surfactin synthetase C-terminal thioesterase domain 
as a cyclic depsipeptide synthase. Biochemistry 2002, 41, (45), 13350-9. 
17. Sieber, S. A.; Marahiel, M. A., Learning from nature's drug factories: 
nonribosomal synthesis of macrocyclic peptides. J. Bacteriol. 2003, 185, (24), 
7036-43. 
18. Kopp, F.; Marahiel, M. A., Macrocyclization strategies in polyketide and 
nonribosomal peptide biosynthesis. Nat. Prod. Rep. 2007, 24, (4), 735-49. 
19. Widboom, P. F.; Fielding, E. N.; Liu, Y.; Bruner, S. D., Structural basis for 
cofactor-independent dioxygenation in vancomycin biosynthesis. Nature 2007, 
447, (7142), 342-5. 
20. Kohli, R. M.; Trauger, J. W.; Schwarzer, D.; Marahiel, M. A.; Walsh, C. T., 
Generality of peptide cyclization catalyzed by isolated thioesterase domains of 
nonribosomal peptide synthetases. Biochemistry 2001, 40, (24), 7099-108. 
21. Trauger, J. W.; Kohli, R. M.; Mootz, H. D.; Marahiel, M. A.; Walsh, C. T., Peptide 
cyclization catalysed by the thioesterase domain of tyrocidine synthetase. Nature 
2000, 407, (6801), 215-8. 
22. Iron Transport and Storage in Microorganisms, Plants, and Animals. Marcel 
Dekker: New York, 1998; Vol. 35, p 775. 
23. Miethke, M.; Marahiel, M. A., Siderophore-based iron acquisition and pathogen 
control. Microbiol. Mol. Biol. Rev. 2007, 71, (3), 413-51. 
24. Cobessi, D.; Celia, H.; Folschweiller, N.; Schalk, I. J.; Abdallah, M. A.; Pattus, F., 
The crystal structure of the pyoverdine outer membrane receptor FpvA from 
Pseudomonas aeruginosa at 3.6 angstroms resolution. J. Mol. Biol. 2005, 347, 
(1), 121-34. 
25. Wirth, C.; Meyer-Klaucke, W.; Pattus, F.; Cobessi, D., From the periplasmic 
signaling domain to the extracellular face of an outer membrane signal 
transducer of Pseudomonas aeruginosa: crystal structure of the ferric pyoverdine 
outer membrane receptor. J. Mol. Biol. 2007, 368, (2), 398-406. 
26. Ikeda, Y.; Furumai, T.; Igarashi, Y., Nocardimicins G, H and I, siderophores with 
muscarinic M3 receptor binding inhibitory activity from Nocardia nova JCM 6044. 
J Antibiot (Tokyo) 2005, 58, (9), 566-72. 
27. Ikeda, Y.; Nonaka, H.; Furumai, T.; Onaka, H.; Igarashi, Y., Nocardimicins A, B, 
C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from 
Nocardia sp. TP-A0674. J. Nat. Prod. 2005, 68, (7), 1061-5. 
28. Kokubo, S.; Suenaga, K.; Shinohara, C.; Tsuji, T.; Uemura, D., Structures of 
Amamistatins A and B, Novel Growth Inhibitors of Human Tumor Cell Lines from 
Nocardia asteroides. Tetrahedron 2000, 56, (35), 6435-6440. 
 192 
29. Harada, K.; Tomita, K.; Fujii, K.; Masuda, K.; Mikami, Y.; Yazawa, K.; Komaki, H., 
Isolation and structural characterization of siderophores, madurastatins, 
produced by a pathogenic Actinomadura madurae. J. Antibiot. (Tokyo) 2004, 57, 
(2), 125-35. 
30. Bauer, A. W.; Kirby, W. M.; Sherris, J. C.; Turck, M., Antibiotic susceptibility 
testing by a standardized single disk method. Am. J. Clin. Pathol. 1966, 45, (4), 
493-6. 
 
 
